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Melanoma, which accounts for only 4% of all skin cancers, but 75% of skin cancer-related 
deaths, continues to rise at an alarming rate worldwide. When a melanoma is detected and 
resected at an early stage, the cure rate for patients is favorable. However, the response rate of 
patients with metastatic melanoma to chemotherapy is less than 15%, and biological therapies 
have limited efficacy. Therefore, identification of genes that can serve as therapeutic targets for 
advanced-stage melanoma is crucial. The cell adhesion molecules N-cadherin, MCAM, and β3 
integrin have been postulated to represent melanoma progression markers; yet, little is known 
regarding whether they may constitute valuable therapeutic targets for the disease. Furthermore, 
no studies conducted to date have examined the expression and function of these three molecules 
in concert in melanoma. The results of our whole-genome and tissue microarray profiling 
illustrate N-cadherin, MCAM, and β3 integrin expression in the distinct stages of melanoma 
progression. We demonstrate that N-cadherin and β3 integrin are melanoma progression markers, 
but MCAM is not. Furthermore, greater than 95% of metastatic melanomas analyzed in our study 
express at least one of the three adhesion molecules, and 50% express all three.  
Our next objective was to determine whether inhibition of N-cadherin, MCAM, or β3 
integrin impairs melanoma cell proliferation, migration, and/or invasion. We hypothesized that 
due to redundancy in the functions of N-cadherin, MCAM, and β3 integrin, simultaneous 
inhibition of all three molecules may elicit the most effective therapeutic response. We 
demonstrate that inhibiting expression of N-cadherin, MCAM, or β3 integrin decreases 
melanoma cell proliferation. However, inhibiting their expression in parallel does not augment 
the anti-proliferative effect. In contrast, downregulation of N-cadherin, MCAM, and β3 integrin 
in parallel inhibits melanoma cell migration and invasion to a significantly greater extent than 
targeting each gene alone. Our results indicate that of the three adhesion molecules, MCAM and 
β3 integrin play the most pronounced role in migration and invasion, and therefore, in 
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combination, may represent the most promising therapeutic targets. The data presented in this 
dissertation provide the foundation for future clinical studies that target adhesion molecules in 
advanced-stage melanoma patients.  
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1.0  INTRODUCTION 
In the last several decades, significant advances have been made in the field of cancer research 
and cancer therapeutics. This progress is attributed to several factors, including an improved 
understanding of the molecular basis of a given malignancy, efforts to emphasize better 
screening and early detection, and clinical implementation of gene targeting approaches for 
selective targeting of tumor cells. The monoclonal antibody Trastuzumab (Herceptin) is one of 
the classic examples of a targeted therapeutic approach, specific for the HER2 protein, and 
approved for advanced-stage HER2-positive breast cancers (as reviewed by Yeon and Pegram, 
2005). Gleevec (Imatinib) is another example of a small molecule tyrosinase kinase inhibitor of 
the BCR-ABL fusion gene, for treatment of chronic myeloid leukemia (Ren, 2005). In the case 
of melanoma, however, the picture is different, because no molecular targeting therapies are yet 
approved, and chemotherapy, despite its lack of efficacy in improving overall survival, remains 
the standard of care for melanoma patients with distant metastases. For this reason, the 
development of novel and effective therapeutic approaches for advanced-stage melanoma 
patients is crucial.  
1.1 MELANOMA 
The three types of skin cancer are basal cell carcinoma, squamous cell carcinoma, and 
melanoma. In the United States, basal and squamous cell carcinomas occur in nearly one million 
cases per year. However, they rarely metastasize, and they have a high cure rate (ACS Cancer 
Facts and Figures 2006). Melanoma, on the other hand, is the most aggressive form of skin 
cancer, and accounts for 75% of all skin cancer-related deaths. The incidence and mortality are 
rising worldwide, and it is predicted that in 2006, melanoma will be diagnosed in approximately 
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62,000 people, with nearly 8,000 deaths (ACS Cancer Facts and Figures 2006). Despite a 
favorable cure rate when surgically removed at an early stage, the response rate of patients with 
metastatic disease to chemotherapy is less than 15%, and 5-year survival rates are between 5 and 
15% (http://seer.cancer.gov). Furthermore, biologic therapies have only a marginal impact. 
Given this bleak picture, there is a great need to identify and characterize genes that play an 
important role in the advanced-stages of the disease and thus, may represent valuable and novel 
targets for therapy.  
1.1.1 Progression Pathway 
Melanocytes are the pigment-producing cells of the epidermis, which reside along the dermal-
epidermal junction in the skin. Keratinocytes, which compose the majority of the cells in the 
epidermis, communicate with the melanocytes and help regulate melanocyte proliferation (Valyi-
Nagy et al., 1993). The primary function of the melanocytes is to synthesize and transport 
melanin to the surrounding keratinocytes via melanosomes, which protects the keratinocytes 
from ultraviolet light (Hsu et al., 2002). Melanoma originates in melanocytes that have 
undergone malignant transformation. Risk factors for melanoma include repeated childhood or 
teenage sunburn, fair complexion, number of pigmented lesions, and a family history of the 
disease (for reviews, see Cummings et al., 1997; Houghton and Polsky, 2002; Tsao et al., 2004). 
In the majority of cases, melanoma arises in or in association with pigmented lesions, called 
nevi. Melanoma develops in distinct stages: atypical nevus > melanoma in situ > primary 
melanoma in the radial growth phase (RGP) > primary melanoma in the vertical growth phase 
(VGP) > metastatic growth phase melanoma (MGP). In RGP melanomas, melanoma cells spread 
horizontally within the confines of the epidermis, while in VGP melanomas, there is invasion of 
the melanoma cells into the dermal layer of the skin (Hsu et al., 2002). The transition from 
melanoma in situ to VGP melanoma, therefore, represents a key transition to the metastasis-
competent stage of the disease.  
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1.1.2 Genes and Pathways Implicated in Melanoma 
As in most other types of cancer, both genetic and environmental factors contribute to the 
development of melanoma. 90% of melanoma cases are of sporadic onset, and 10% of cases are 
of familial onset. Several studies have investigated chromosomal alterations in familial and 
sporadic melanomas. The most prominent germline mutations identified for familial melanoma 
to date are the tumor suppressor gene CDKN2A (which encodes INK4A/p16 and ARF), and the 
cyclin-dependent kinase 4 (CDK4) gene (Fountain et al., 1992; Loo et al., 2003; Soufir et al., 
2004; Puig et al., 2005). The product of the CDKN2 gene is p16, which binds CDKs to inhibit 
their association with cyclin D, and blocks cell cycle progression at the G1 phase (Serrano et al., 
1993). Mutations in these cell cycle regulators can mediate deregulation of cell growth during 
tumorigenesis. CDKN2/p16 has also been shown to be mutated in a small percentage of sporadic 
melanomas (Piccinin et al., 1997).  
Polymorphisms of the melanocortin-1 receptor (MC1R), a seven-transmembrane G-
protein-coupled receptor, whose ligand is melanocyte-stimulating hormone (MSH), have also 
been indirectly associated with melanoma predisposition (Chin, 2003). MC1R and MSH are 
critical components of the pigmentation pathway, and MC1R variants influence skin and hair 
coloring, with specific variants associated with the “red hair color (RHC)” phenotype (Flanagan 
et al., 2000). Because, as mentioned above, fair skin pigmentation is a significant risk factor for 
melanoma, it is hypothesized that polymorphisms in the MC1R gene may contribute to 
melanoma susceptibility. Interestingly, mutations in MC1R have been associated with reduced 
ability of melanocytes to protect against ultraviolet radiation (Scott et al., 2002).  
A variety of different pathways have been implicated in melanoma development and 
progression. For example, melanoma cells, unlike melanocytes, produce growth factors that can 
function in an autocrine or paracrine manner, and therefore, lose their dependence upon external 
growth factors for survival. bFGF/FGFR-1 is the most prominently implicated growth factor 
signaling pathway in melanoma development and progression (Becker et al., 1989; Becker et al., 
1992; Wang and Becker, 1997). Hepatocyte growth factor (HGF)/cMET (Otsuka et al., 1998) 
and transforming growth factor-β (TGF-β) (Hussein, 2005) have also been postulated to 
influence to melanoma development; however, these two pathways appear to be limited to a 
small fraction of melanomas.  
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The mitogen-activated protein kinase (MAPK) signaling pathway plays an integral role in 
the regulation of cell proliferation and survival. Somatic mutations resulting in constitutive 
activation of this RAS-RAF-ERK pathway, in particular, mutations in B-RAF, have been 
identified in a large percentage of melanoma cell lines and tissue specimens (for review, see 
Gray-Schopfer et al., 2005). One of several similar studies established that B-RAF is mutated in 
approximately 66% of malignant melanomas (Davies et al., 2002), usually within the kinase 
domain. A recent study has demonstrated an association between MC1R variants and increased 
frequency of mutations in B-RAF (Landi et al., 2006).  
Mutations in the tumor suppressor PTEN, which negatively regulates the PI3K/AKT 
pathway and may result in increased activation of AKT, are hypothesized to reduce the 
sensitivity of melanoma cells to apoptosis (Stahl et al., 2004; Dai et al., 2005; Robertson, 2005). 
In addition, the transcription factors Nf-κb (for review, see Amiri and Richmond, 2005), as well 
as signal transducers and activators of transcription (STATs) (Kirkwood et al., 1999), have 
emerged as regulators of gene expression in melanoma. From the implicated pathways, it is 
evident that deregulation of melanocyte/melanoma proliferation and survival are key events in 
melanoma pathogenesis. The ability to identify changes in these signaling pathways in patients 
with melanoma will facilitate the development of targeted therapeutic approaches for this 
disease.  
1.1.3 Current Clinical Therapies 
The current therapeutic options for metastatic melanoma are only marginally effective (for 
reviews, see Tsao et al., 2004; Atallah and Flaherty, 2005). The alkylating agent dacarbazine 
(DTIC) is the only chemotherapeutic reagent that is currently FDA-approved for melanoma and 
is considered the standard regimen for Stage IV melanoma. The objective response rate to DTIC 
is barely 10-20%, there is generally only a partial response, and overall survival is not improved 
significantly (Luikart et al., 1984; Chapman et al., 1999; Eggermont and Kirkwood, 2004). 
Likewise, other chemotherapeutic drugs, such as cisplatin and temozolomide, have shown only 
modest activity in clinical trials to date (Eigentler et al., 2003), and numerous clinical trials have 
failed to demonstrate that combining other chemotherapeutic drugs with DTIC yields any 
 6 
consistent improvement in response rate compared with DTIC alone (Eggermont and Kirkwood, 
2004).  
In addition to standard chemotherapy regimens, cytokine therapy is another approach that 
is used for melanoma therapy. High dose interferon alpha 2b (IFNα2b), an FDA-approved 
cytokine therapy for melanoma, yields modest improvements in relapse-free and overall survival 
as an adjuvant therapy in stage IIb and stage III melanoma patients. However, toxicity associated 
with the drug is high (Kirkwood et al., 2002), and response rates for IFNα2b average around 10-
15% (Atallah and Flaherty, 2005). IL-2 therapy generated an overall response of 16% in a trial 
composed of 270 patients with metastatic melanoma, but, as with IFNα2b, toxicity was high 
(Atkins et al., 1999). To date, no survival benefit has been demonstrated following combination 
of DTIC with IFNα2b and IL-2, compared with DTIC alone (Atkins et al., 2003; Keilholz et al., 
2005).  
As discussed above, somatic B-RAF mutations that result in increased kinase activity are 
detected in approximately 66% of malignant melanomas (Davies et al., 2002). The small 
molecule inhibitor, Nexavar (sorafenib, BAY 43-9006), inhibits the RAF kinase pathway, and, to 
some degree, the receptor tyrosine kinases VEGFR-2/3 and PDGFR-β (Wilhelm et al., 2004; 
Sridhar et al., 2005; Flaherty, 2006). Nexavar was one of the first small molecule inhibitors used 
for specific gene targeting in the treatment of advanced-stage melanoma. Early phase I/II trials 
showed activity of the drug in stage IV melanoma patients (Ahmad et al., 2004). Phase II and III 
trials are presently examining the efficacy of Nexavar in combination with temsirolimus, 
tipifarnib, or a combination of carboplatin and paclitaxel, in stage III/IV melanoma patients 
(www.clinicaltrials.gov).  
In summary, it is clear from these clinical trial data that it is imperative that we develop 
novel therapeutic approaches for advanced-stage melanoma that are more specific, generate a 
more robust tumor response, and increase patient survival.  
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1.2 ADHESION MOLECULES 
1.2.1 Invasion and Metastasis 
In general, the cause of death from cancer is not attributed to the burden from the primary tumor, 
but to the metastasis of tumor cells to distant sites. In the case of melanoma, prognosis is directly 
related to the depth of invasion of the primary lesion at the time of diagnosis. During the process 
of metastasis, tumor cells detach from the primary tumor, migrate across the basement 
membrane, enter and spread throughout the circulatory system, and establish at distant sites. The 
metastatic tumor cell must therefore acquire the ability to migrate away from the primary site, to 
interact with different cell types encountered during invasion, and to proliferate and survive in 
the new tumor microenvironment (for review, see Chambers et al., 2002).  
Two distinct hypotheses regarding the acquisition of metastatic potential have been 
described. The “seed and soil” hypothesis suggests that metastasis only occurs when the tumor 
cell (the seed) grows in the correct tumor microenvironment (the soil) (Fidler, 2001). In this 
model, interactions between tumor and host cells are crucial in mediating metastasis. On the 
other hand, Robert Weinberg and colleagues described a model whereby tumor progression and 
metastasis are “pre-programmed” at an early stage of tumor progression by genetic alterations, 
and that furthermore, the same oncogenes and tumor suppressors that mediate tumor initiation 
likely mediate subsequent tumor metastasis (Bernards and Weinberg, 2002). Whether one or a 
combination of both models represents the correct mechanism underlying tumor metastasis 
remains to be determined. Further understanding regarding the mechanism of the metastasis will 
be essential in the development of cancer therapeutics that can prevent the spread of tumors cells 
to distant sites.  
1.2.2 Expression of Cell Adhesion Molecules in Melanoma 
Cell adhesion molecules play a critical role in cancer metastasis by regulating tumor cell-cell and 
cell-extracellular matrix (ECM) adhesion. In addition, they mediate signal transduction following 
cell-cell and cell-ECM interactions. Tumor cells frequently display altered expression of cell 
adhesion molecules, which has been implicated in tumor invasion and metastasis in many cancer 
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types (Christofori, 2003), including melanoma (Johnson, 1999). Three cell adhesion molecules 
have been postulated to serve as progression-related factors in melanoma: N-cadherin, melanoma 
cell adhesion molecule (MCAM), and the β3 integrin subunit. These represent three distinct 
families of cell adhesion molecules: the cadherins, the immunoglobulin superfamily, and the 
integrins, respectively.  
1.2.3 N-cadherin 
The cadherins mediate calcium-dependent cell-cell adhesion, usually through homophilic 
binding at cell-cell junctions. Classical cadherins are composed of a single transmembrane 
domain, with the extracellular portion containing multiple calcium-binding domains. The 
cytoplasmic region interacts with catenins to provide a link to the actin cytoskeleton (Figure 1).  
 
 
Figure 1: N-cadherin Structure 
Classical cadherins are composed of a short cytoplasmic domain, a single transmembrane region, and 
multiple extracellular domains. The cytoplasmic domain interacts with catenins and links to the actin 
cytoskeleton. The extracellular domains contain Ca2+-binding sites that stabilize the cadherin structure 
and facilitate interaction with cadherins on the surface of other cells. The His-Ala-Val (HAV) domain 
mediates specific cadherin-cadherin interactions.  
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Cadherins are essential for tissue development and are crucial for epithelial to 
mesenchymal transitions (Thiery, 2002). Homozygous deletion of E-cadherin (Larue et al., 1994) 
or N-cadherin (Radice et al., 1997) causes embryonic lethality in mice. The cadherins have 
emerged as important players in tumorigenesis, with changes in cadherin expression profiles 
frequently observed during tumor progression. Most prominently, a switch from E-cadherin to 
N-cadherin expression has been documented in numerous tumors of epithelial origin, including 
melanoma, breast, prostate, bladder, and squamous cell carcinoma (for review, see Cavallaro, 
2004). The loss of E-cadherin expression can be genetic, through germline mutations (Guilford 
et al., 1998; Richards et al., 1999) or epigenetic, where downregulation at the transcriptional 
level is most common, through transcriptional repressors including SNAIL (Poser et al., 2001) 
and SLUG (Bolos et al., 2003), and/or promoter hypermethylation (Chen et al., 2003).  
Cadherins also play a key role in the development and differentiation of human skin 
(Herlyn et al., 2000). The epidermis is composed primarily of keratinocytes and melanocytes, at 
a ratio of approximately 5-10:1. Melanocyte proliferation is carefully regulated by signaling 
from the keratinocytes. Keratinocytes and melanocytes both express E-cadherin, which has been 
shown to mediate interactions and communication between the two cell types (Valyi-Nagy et al., 
1993). Notably, however, expression of E-cadherin is significantly reduced or absent in most 
human melanoma cell lines, while N-cadherin, which is not expressed by melanocytes in normal 
skin, is highly expressed (Hsu et al., 1996). A general pattern toward decreased expression of E-
cadherin and increased expression of N-cadherin in MGP melanoma tissue specimens has been 
suggested (Danen et al., 1996; Hsu et al., 1996; Sanders et al., 1999), although the expression 
patterns in these reports were variable in the small number of tissue samples assayed. 
Based on these findings, a loss of E-cadherin expression and/or de novo N-cadherin 
expression in the melanocytes may impair their interactions with keratinocytes. A loss of 
communication between the two cell types may thereby promote melanocyte proliferation and 
migration. This hypothesis is supported by experiments in several cell types. First, re-expression 
of E-cadherin in an E-cadherin negative melanoma cell line inhibits invasion in skin reconstruct 
models, and reduces growth in soft agar and tumor formation in nude mice (Hsu et al., 2000). 
Second, in the E-cadherin-expressing MCF7 breast cancer cell line, exogenous expression of N-
cadherin increases cell migration, invasion, and adhesion to endothelial cells in vitro, and 
increases metastasis in vivo (Hazan et al., 2000). Finally, transfection of a squamous cell 
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carcinoma cell line with antisense N-cadherin results in a change from scattered fibroblastic to 
normal epithelial morphology, and a re-induction of E-cadherin expression (Islam et al., 1996).  
Because N-cadherin is expressed by fibroblasts and vascular endothelial cells, it is 
possible that N-cadherin expression may promote the interaction of melanoma cells with these 
cell types during invasion and metastasis. Transendothelial migration assays indicate that N-
cadherin is expressed in regions of heterotypic contact between melanoma and endothelial cells 
during the transmigration (Sandig et al., 1997). It has also been reported that N-cadherin can 
mediate adhesion between melanoma cells and dermal fibroblasts/vascular endothelial cells in 
vitro. Furthermore, an N-cadherin blocking antibody inhibits the migration of melanoma cells 
across a monolayer of fibroblasts (Li et al., 2001).  
N-cadherin expression has been linked to several signal transduction pathways. An N-
cadherin antibody inhibits the phosphorylation of Akt/PKB in melanoma cells (Li et al., 2001). 
Likewise, N-cadherin expression in prostate cancer cells has been implicated in upregulation of 
Bcl-2 and activation of PI3 kinase/Akt (Tran et al., 2002). Furthermore, in breast cancer cells, a 
direct association between N-cadherin and fibroblast growth factor receptor-1 (FGFR-1) occurs, 
resulting in a decrease in ligand-induced receptor downregulation and sustained MAPK/ERK 
activation (Suyama et al., 2002). From these studies, it is clear that N-cadherin mediates tumor 
cell-cell interactions, as well as signal transduction pathways involved in cell proliferation and 
migration, and represents an intriguing molecule for further analysis in melanoma.  
1.2.4 MCAM  
Cell adhesion molecules of the immunoglobulin (Ig) superfamily mediate cation-independent 
cell-cell adhesion, which can be either homophilic or heterophilic (Johnson, 1991). MCAM is a 
113 kD integral membrane protein, with an extracellular domain composed of repeated Ig-like 
folds, stabilized by disulfide bonds (Figure 2). The cytoplasmic domain contains several putative 





Figure 2: MCAM Structure 
MCAM is composed of a short cytoplasmic domain, a single transmembrane domain, and an extracellular 
domain containing five immunoglobulin-like units (V-V-C2-C2-C2). MCAM interacts with an as yet 
unknown receptor. 
 
MCAM was first identified on MGP melanoma cells (Lehmann et al., 1987), but is also 
expressed in cell types including endothelial, smooth muscle, activated T lymphocytes, and hair 
follicles (Lehmann et al., 1987; Shih et al., 1997). MCAM expression has also been documented 
in prostate carcinoma (Wu et al., 2001), choriocarcinoma, angiosarcoma, Kaposi’s sarcoma, and 
leiomyosarcoma (Shih et al., 1998). MCAM is not expressed by melanocytes in normal skin; 
however, when melanocytes are propagated in vitro, they begin to express MCAM (Shih et al., 
1994). MCAM interacts heterophilically with an as yet unidentified ligand that is typically co-
expressed with MCAM on melanoma cells (Johnson, 1997; Shih et al., 1997). In human tissues, 
an early study reported that greater than 70% of melanoma metastases express MCAM and that 
its expression correlates with increasing tumor thickness (Holzmann et al., 1987). Furthermore, it 
has been suggested that loss of expression of the transcription factor AP-2 may mediate MCAM 
upregulation in advanced-stage melanoma (Jean et al., 1998).  
Several studies have implicated MCAM in melanoma invasion in vitro and metastasis in 
vivo. Transfection of an MCAM-negative melanoma cell line with an MCAM cDNA was 
reported to increase invasion, attachment to endothelial cells, subcutaneous tumor formation, and 
lung metastases formation in nude mice (Xie et al., 1997; Schlagbauer-Wadl et al., 1999). 
MCAM-positive cells also displayed reduced adhesion to laminin (Xie et al., 1997). Another 
study reported that inhibiting MCAM expression in melanoma cells may lead to loss of gap-
junction communication, as evidenced by reduced invasion in a 3D skin reconstruct model 
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(Satyamoorthy et al., 2001). Furthermore, an MCAM antibody decreases melanoma cell 
invasion, tumor vascularization, and MMP-2 expression, and reduces formation of lung 
metastasis in nude mice (Mills et al., 2002).  
MCAM expression is thought to play a role in several signal transduction pathways. A 
reciprocal relationship between MCAM expression and Akt phosphorylation in melanoma cells 
has been suggested. Blocking Akt activation results in decreased MCAM expression, while 
overexpression of MCAM, likewise, increases phosphorylation of Akt and Bad (Li et al., 2003). 
In addition, engagement of MCAM in endothelial cells leads to tyrosine phosphorylation of focal 
adhesion kinase (p125FAK/FAK) (Anfosso et al., 1998). Overall, these results demonstrate that 
MCAM, like N-cadherin, plays a role in both cell-cell interactions and signal transduction in 
melanoma cells.  
1.2.5 β3 integrin 
Integrins are heterodimeric cell surface receptors, which mediate divalent cation-dependent cell-
matrix interactions. Integrin complexes are composed of an alpha and a beta subunit, which are 
non-covalently associated. Different combinations of alpha and beta subunits convey ligand 
specificity. Most integrin subunits are composed of a large extracellular domain, a single 
transmembrane region, and a short cytoplasmic domain (Figure 3). The cytoplasmic tail of the 
beta subunit binds to intracellular proteins, including α-actinin and filamin, to provide a physical 
linkage between the ECM and the cytoskeleton. The alpha and beta cytoplasmic tails also 
associate with a variety of adaptor proteins, including Shc, Grb2, paxillin, and FAK, which 
provides a mechanism for intracellular signaling (Berman et al., 2003).  
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 Figure 3: Integrin Structure 
Integrins are composed of an α and β subunit, which are non-covalently associated. The extracellular 
regions of the integrin subunits bind to ECM ligands, with ligand specificity determined by the particular 
combination of α and β subunits. The cytoplasmic tail of the β subunit binds to intracellular proteins that 
anchor to the cytoskeleton, thus providing a physical linkage between the ECM and the cytoskeleton. The 
α and β cytoplasmic tails also associate with a variety of adaptor proteins, which can mediate intracellular 
signaling.  
 
αvβ3 integrin is one of the most “promiscuous” integrin receptors, recognizing ligands 
including vitronectin, fibrinogen, von Willebrand factor, fibronectin, laminin, thrombospondin, 
and osteopontin (Cheresh, 1991). αvβ3 is expressed by vascular endothelial cells, smooth muscle 
cells, osteoclasts, macrophages, and some lymphocytes (B-cells, T-cells, and NK cells) (Nip and 
Brodt, 1995). β3 integrin is not expressed by melanocytes in normal skin. However, in 
melanoma, expression of the β3 integrin subunit is associated with the transition from RGP to 
VGP melanoma (Albelda et al., 1990). The αv subunit, on the other hand, is expressed 
throughout all stages of melanoma progression.  
Exogenous expression of β3 integrin in RGP melanoma cells increases invasion in a skin 
reconstruct model and increases tumorigenicity in SCID mice (Hsu et al., 1998). αvβ3 has also 
been implicated in transendothelial migration of melanoma cells in culture, with strong 
expression in regions of heterotypic contact between melanoma and endothelial cells (Voura et 
al., 2001). β3 integrin expression has been linked with the activation of focal adhesion kinase 
(FAK) (Li et al., 2001), the production of mature MMP-2 and MMP-9 (Brooks et al., 1996; 
Felding-Habermann et al., 2002; Rolli et al., 2003), and the activation of Akt (Zheng et al., 
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2000). In melanomas, expression of αvβ3 integrin is associated with increased tumor thickness, 
reduced disease-free and overall survival (Hieken et al., 1996), and elevated risk of melanoma 
recurrence (Natali et al., 1997).  
The suggestion that αvβ3 integrin plays a crucial role in angiogenesis was based initially 
on studies using a function-blocking αvβ3 integrin antibody to inhibit the growth of human tumor 
fragments implanted onto chicken chorioallantoic membrane (CAM) (Brooks et al., 1994; 
Brooks et al., 1994). These studies generated substantial enthusiasm for αvβ3 integrin as a 
putative therapeutic target for inhibiting angiogenesis in diseases including cancer, diabetic 
retinopathy, and rheumatoid arthritis. However, studies with β3 integrin knockout mice have 
challenged the hypothesis that β3 integrin functions exclusively as a pro-angiogenic molecule. 
β3-deficient mice are viable and fertile, with defects in platelet aggregation and clot retraction, 
and prone to prolonged bleeding (Hodivala-Dilke et al., 1999). Unexpectedly, however, mice 
deficient in β3 integrin or both β3/β5 integrin display enhanced tumor growth and angiogenesis 
compared with controls (Reynolds et al., 2002; Taverna et al., 2004). This experimental outcome 
generated uncertainty with respect to the role of β3 integrin in angiogenesis and tumorigenesis. 
Future studies will be necessary, to further elucidate the mechanism of β3 integrin in 
tumorigenesis and determine its value as a therapeutic target.  
1.2.6 Clinical Trials 
Ongoing clinical trials address the potential of adhesion molecules as therapeutic targets for 
cancer. An N-cadherin cyclic peptide inhibitor, Exherin™ (Adherex Technologies, Inc.) is 
designed to target N-cadherin interactions and is thought to block the interaction between 
endothelial cells and/or tumor cells (Williams et al., 2000). Exherin contains the His-Ala-Val 
(HAV) sequence, which is located in the extracellular region of N-cadherin near the N-terminus 
and mediates cadherin cell-cell adhesion. In a phase I trial comprised of patients with N-
cadherin-positive tumors of various cancer types, Exherin was well tolerated, and modest anti-
tumor activity was observed in two patients (Jonker et al., 2004). An ongoing phase II trial 
further investigates the efficacy of this drug (www.clinicaltrials.gov). In the case of MCAM, the 
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humanized antibody described by Mills et al, 2002 (ABX-MA1), developed by Abgenix, and had 
entered phase I clinical trials for melanoma. However no follow-up information is available.   
In addition to the targeting agents described above, inhibitors of integrin subunits are the 
focus of several clinical trials. Cilengitide, an Arg-Gly-Asp (RGD) peptide that blocks both αvβ3 
and αvβ5 integrin, is currently in phase I/II trials for cancers including head and neck, 
glioblastoma, non-small-cell lung, and pancreatic (Smith, 2003). However, therapeutic efficacy 
has not been demonstrated to date. Additional integrin antagonists are in the early stages of 
clinical investigation, including CNTO 95 (αv), Volociximab (α5β1), and ATN-161 (α5β1, αvβ3) 
(Tucker, 2006). In the case of melanoma, Phase I/II trials are investigating 
Abegrin/Vitaxin/MEDI-522, a humanized monoclonal antibody that blocks αvβ3 integrin 
(Gutheil et al., 2000; Posey et al., 2001; Shreyaskumar et al., 2001). Abegrin is thought to 
function as an anti-angiogenic inhibitor, through inhibition of tumor blood vessel growth. An 
ongoing phase II study is examining the efficacy of Abegrin in stage IV melanoma patients. 
Results obtained to date indicate that although patients with MGP melanoma treated with this 
antibody have no objective tumor response, they live longer compared to historic controls 
(Hersey et al., 2005). The results of these ongoing studies will help indicate whether blocking the 
function of integrins represents a viable approach for cancer therapy.  
1.3 RATIONALE AND HYPOTHESIS 
Data in the literature suggest that N-cadherin, MCAM, and β3 integrin may contribute to 
melanoma progression. Yet, little is known as to whether they may constitute therapeutic targets 
for the disease, and, equally importantly, no previous studies have examined the expression or 
function of the three adhesion molecules in concert. In this dissertation, we will illustrate the 
expression of N-cadherin, MCAM, and β3 integrin mRNA and protein throughout the distinct 
stages of melanoma progression using microarray analyses, and, in addition, evaluate whether 
MGP melanomas co-express all three adhesion molecules. This critical question will help to 
establish whether all three adhesion molecules are essential for melanoma metastasis. Next, we 
will test our hypothesis that individual inhibition of N-cadherin, MCAM, or β3 integrin in 
melanoma cells may decrease proliferation, migration, and/or invasion. However, it is important 
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to note that research to date has indicated substantial redundancy in the signaling pathways for 
N-cadherin, MCAM, and β3 integrin, including bFGF/FGFR-1, FAK, MMP’s, MAPK/ERK, 
Akt/PKB, and others (Xie et al., 1997; Anfosso et al., 2001; Hood and Cheresh, 2002; Derycke 
and Bracke, 2004). As such, it is possible that upon inhibition of one of these molecules, the 
other two may readily compensate for any anti-tumorigenic impact. Therefore, this dissertation 
will also evaluate our hypothesis that simultaneous inhibition of multiple adhesion molecules 
may be required for the most effective inhibition of melanoma cell proliferation, migration, 
and/or invasion. Given the lack of effective therapeutic strategies for advanced-stage melanoma, 
our data will provide valuable evidence as to whether these cell adhesion molecules, alone or in 
concert, represent useful and effective therapeutic targets for advanced-stage melanoma.  
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2.0  MATERIALS AND METHODS 
2.1 CELL CULTURE 
The human metastatic (MGP) melanoma cell lines, WM1158, WM852, and WM983B, were 
cultured in 3 parts DMEM, 1 part L-15 (Mediatech, Herndon, VA), and 10% heat-inactivated 
fetal bovine serum (FBS) (HyClone, Logan, UT) and 100 µg/mL penicillin-streptomycin. Cells 
were maintained at 37°C and 5% CO2.  
2.2 RT-PCR 
Total RNA was isolated from WM1158, WM852, and WM983B cells using TRIzol reagent 
(Invitrogen, Carlsbad, CA). RT-PCR was performed to amplify N-cadherin, MCAM, and β3 
integrin cDNA (1.9, 1.8, and 2.3 kb fragments, respectively). Primer sequences were as follows: 
N-cadherin (Forward: 5’-AGACTGGATTTCCTGAAG-3’, Reverse: 5’GGGAACTT 
CATAGATACC-3’); MCAM (Forward: 5’-AGCACAGCCCTTCTGAAG-3’, Reverse: 5’-
ATTTCTCTCCCTGCTCTC-3’); β3 integrin (Forward: 5’AACATCT GTACCACGCGA3’, 
Reverse: 5’CGTGATATTGCTGAAGGT3’.  
2.3 WHOLE-GENOME MICROARRAY ANALYSIS 
Total RNA was extracted from tissue specimens - two normal skin, two benign nevi, two 
atypical nevi, two melanomas in situ, two primary melanomas (VGP), two metastatic melanomas 
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(MGP), and three melanoma-infiltrated lymph nodes, as well as from WM1158 cells, with the 
RNeasy Lipid Midi Extraction Kit (Qiagen, Valenica, CA). RNAs were subsequently processed 
using the RNeasy Mini Kit RNA clean-up protocol (Qiagen). Human neonatal melanocyte 
(HEMn) and keratinocyte (HEKn) RNA were obtained from Cell Applications, Inc. Samples 
were analyzed on an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA) to verify 
RNA integrity. RNAs were transcribed into cRNAs, biotinylated, and hybridized to Human 
Genome U133 Plus 2.0 gene chip microarrays (Affymetrix, Santa Clara, CA) (Smith et al., 
2005). Normalization of intensity values was performed using GeneSpring 7.1 bioinformatics 
software (Silicon Genetics, Agilent Technologies).  
2.4 TISSUE MICROARRAY ANALYSIS 
Nevus, VGP, MGP, and melanoma-infiltrated lymph node TMAs were constructed by the 
National Cancer Institute - Center for Cancer Research (NCI-CCR) Tissue Array Research 
Program (TARP). TMA slides were deparafinized and rehydrated, following by antigen 
unmasking using Target Retrieval buffer, pH 6 (Dako, Glostrup, Denmark) in a decloaking 
chamber. Endogenous peroxidases were then quenched using 3% hydrogen peroxide. Standard 
immunohistochemistry was performed using the VECTASTAIN elite ABC kit (Vector 
Laboratories, Burlingame, CA). Tissue cores were probed with antibody to N-cadherin (sc-7939, 
rabbit polyclonal, 1:50), MCAM (sc-18942, goat polyclonal, 1:50), or β3 integrin (sc-13579, 
mouse monoclonal, 1:100) (Santa Cruz Biotechnology, Santa Cruz, CA). As a negative control, 
each array was also probed with antibody to PERP (ab-5986, rabbit polyclonal, 1:250, ABCAM, 
Cambridge, MA). Peroxidase substrate was NovaRED (Vector Laboratories). Slides were 
counterstained with hematoxylin, dehydrated, and mounted in non-aqueous mounting media.  
TMAs were scored using a scale of 0 (no signal), 1 (weakly positive), or 2 (strongly 
positive). The total number of tissue cores scored for N-cadherin expression were nevi (38), VGP 
melanomas (43), MGP melanomas (60), melanoma-infiltrated lymph nodes LN (30); for MCAM 
expression: nevi (43), VGP melanomas (35), MGP melanomas (66), melanoma-infiltrated lymph 
nodes (35); and for β3 integrin expression: nevi (63), VGP melanomas (36), MGP melanomas 
(68), melanoma-infiltrated lymph nodes (38).  
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2.5 RNA INTERFERENCE 
N-cadherin individual siGENOME duplex (5’-GAAACTTGCTGACATGTAT-3’), and MCAM 
siRNA duplex (5’-AAGATCCACAGCGAGTCCTGA-3’) were purchased from Dharmacon 
(Lafayette, CO). Pre-designed β3 integrin silencer siRNA (5’-GGAGAATCTGCTGAAGGAT-
3’), and a scrambled siRNA negative control were purchased from Ambion (Austin, TX). 
Melanoma cells were transfected with 100 nM siRNA mixed with Lipofectamine 2000 
(Invitrogen), as per the manufacturer’s recommendations. For combined treatment with multiple 
siRNAs, a mixture of 100 nM of each siRNA was used. 48 or 72 hours post-transfection, cell 
lysates were subjected to immunoblot analysis.  
N-cadherin, MCAM, and β3 integrin siRNAs were labeled with Cy3, by way of a Silencer 
siRNA Labeling Kit (Ambion), and transfected into WM1158 cells. The cells were imaged in the 
Cy3 channel.  
2.6 ANTISENSE VECTOR CONSTRUCTS 
Total RNA was extracted from WM1158 cells using TRIzol reagent (Invitrogen). RT-PCR was 
performed to amplify partial cDNA transcripts of N-cadherin (2.0 kb), MCAM (1.1 kb), and β3 
integrin (1.3 kb). The primer sequences included the restriction sites XhoI or BamHI for sub-
cloning (underlined): N-cadherin (Forward: 5’GCCATGGGATCCATGTG 
CCGGATAGCGGGA3’, Reverse: 5’GCTGTACTCGAGGGGAACTTCATAGATACC3’) - 
NCBI sequence X54315 nucleotide 102-2121; MCAM (Forward: 5’GCCAGTGGATCCAG 
CATGGGGCTTCCCAGG3’, Reverse:  5’GCTGTACTCGAGTGCCTCACAGGTCAGGGT3’) 
- NCBI sequence M28882 nucleotide 5-1108; β3 integrin (Forward: 5’GCCAGTG 
GATCCAACATCTGTACCACGCGA3’, Reverse:  5’GCTGTACTCGAGGGTCCCAATG 
CCATTGTT3’ - NCBI sequence NM_000212 nucleotide 101-1439. Each of the cDNA 
sequences were subcloned, in their antisense orientation, into the multiple cloning site of the 
cytomegalovirus (CMV) promoter-driven pcDNA3.1 Hygro (-) mammalian expression vector 
(Invitrogen). Sequencing analysis was performed to verify correct insertion and orientation of the 
cDNAs.  
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N-cadherin, MCAM, and β3 integrin antisense plasmids, as well as empty pcDNA 3.1 
plasmid, were transfected into WM983B cells using Lipofectamine 2000 (Invitrogen), as per the 
manufacturer’s recommendations. Stable transfectants were selected in the presence of 150 
µg/mL hygromycin B (Invitrogen). Individual hygromycin-resistant colonies were isolated and 
screened for reduction of respective protein levels compared with controls, by immunoblot 
analysis.  
2.7 IMMUNOBLOTTING 
Total cell lysates were prepared using Cell Lysis Buffer (Cell Signaling Technology, Danvers, 
MA) supplemented with 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich, St. Louis, MO), 
as per manufacturer’s instructions. Lysates were separated on 8% SDS-PAGE gels and 
transferred to nitrocellulose (Biorad, Hercules, CA) or PVDF (Millipore, Billerica, MA) 
membrane. Following blocking with 5% dry milk/TBST (10 mM Tris pH 8.0, 150 mM NaCl, 
0.05% Tween), the membranes were probed with antibodies to N-cadherin, MCAM, β3 integrin, 
E-cadherin (Santa Cruz Biotechnology); pAKT (Ser473) (Cell Signaling Technology); αv 
integrin (BD Biosciences, San Diego, CA); or actin (ABCAM), all diluted in TBST. Membranes 
were washed three times with TBST for 5 minutes each, and then probed with secondary 
antibody. After three washes for 5 minutes each with TBST and a 5-minute wash with TBS 
(without Tween), signals were visualized using Immobilon Western Chemiluminescent HRP 
Substrate (Millipore). ImageJ densitometry software was used for quantification of levels of 
protein expression.  
2.8 IMMUNOHISTOCHEMISTRY 
Snap-frozen tissue specimens were embedded in O.C.T. (Tissue-Tek, Sakura Finetech U.S.A., 
Inc., Torrance, CA), and 5 µm sections were prepared and fixed in ice-cold acetone. Standard 
immunohistochemistry was performed using the R.T.U VECTASTAIN elite ABC kit (Universal) 
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(Vector Laboratories). The tissue sections were probed with antibody to N-cadherin (sc-7939, 
rabbit polyclonal), MCAM (sc-18942, goat polyclonal), or β3 integrin (sc-6626, goat polyclonal) 
(Santa Cruz Biotechnology), at a dilution of 1:20, or osteopontin (rabbit polyclonal, LabVision, 
Freemont, CA), at a dilution of 1:50. These incubations were performed in a humidified 
incubator, at 37°C. The peroxidase substrate was AEC (Vector Laboratories).  
2.9 IMMUNOFLUORESCENCE AND PHASE-CONTRAST IMAGING   
Melanoma cells were plated on coverslips in 24-well culture dishes. Cells were fixed in ice-cold 
acetone, rehydrated in PBS, and blocked with 2.5% normal goat serum (Vector Laboratories). 
Cells were probed with primary antibody, as described in Section 2.8, and then probed with 
FluoroLink Cy5-conjugated secondary antibody at a 1:1000 dilution (Amersham Biosciences, 
Piscataway, NJ). Fluorescent DAPI (Molecular Probes, Invitrogen) was used as a nuclear 
counterstain. Incubations were performed at 37°C in a humidified incubator. Fluorescent signal 
was visualized using a Nikon TE2000 microscope, with Photometrics CoolSNAP HQ charge-
coupled device (CCD) camera (Roper Scientific, Tuscon AZ), 40X oil immersion objective, and 
DAPI or Cy5 excitation/emission filters. Images were acquired using MetaMorph® imaging 
software (Universal Imaging, Sunnyvale, CA).  
Phase-contrast images of antisense-transfected or control vector only-transfected MGP 
melanoma cells were captured, using a 10X objective, with phase-contrast light settings.  
2.10 APOPTOSIS  
Apoptosis was assessed in cultured melanoma cells using the TMR Red In Situ Cell Death 
Detection Kit (Roche Applied Science, Indianapolis, IN), as per the manufacturer’s instructions. 
For positive control, cells were pre-treated with 500 U/mL DNase I, for 10 minutes at room 
temperature. For negative control, cells were incubated in the absence of terminal transferase 
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enzyme. A 40X oil immersion objective and Cy3 excitation/emission filters were utilized to 
acquire images of cells having undergone apoptosis.  
2.11 MELANOMA CELL PROLIFERATION 
Melanoma cells were seeded, in triplicate, into 24-well plates, at a density of 7x104 cells per 
well. Following siRNA transfection, adherent cells were detached with trypsin/ 
ethylenediaminetetraacetic acid (EDTA), and counted using a hemacytometer. Replicate counts 
were averaged for each sample.  
Proliferation rates of the pcDNA N-cadherin, MCAM, and β3 integrin antisense-
transfected cells and control pcDNA vector-transfected cells were determined via the MTT 
colorimetric assay. 1x104 cells were plated in quadruplicate in 96 well dishes. At the indicated 
times, the media was replaced with phenol red-free media, and 10 µl of 12 mM MTT solution (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well, and 
samples were incubated at 37°C for 4 hours. Thereupon, 100 µl of 10% SDS in 0.01 M HCl was 
added to each well, and cells were incubated overnight at 37°C. Samples were read at an 
absorbance of 570 nm.  
2.12 MELANOMA CELL MIGRATION AND INVASION 
For determination of melanoma cell migration and invasion, at 48 hours post siRNA transfection, 
cells were trypsinized and resuspended in serum-free media. 4x104 cells were plated per well, in 
triplicate, into transwell migration chambers, containing an 8 µm pore-size filter with (for 
analysis of invasion) or without (for analysis of cell migration) a Matrigel coating (BD 
Biosciences). Heat-inactivated 5% fetal bovine serum (FBS), mixed with Dulbecco's Modified 
Eagle's Medium (DMEM), served as chemoattractant in the lower wells. Twenty-two hours later, 
cells that had migrated to the lower side of the filter(s) were fixed, stained, and counted in seven 
randomly selected 40x fields/filter.  
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2.13 IN VIVO GROWTH OF ANTISENSE-TRANSFECTED CELLS 
N-cadherin, MCAM, or β3 integrin antisense-transfected cells, pcDNA vector only-transfected 
cells, or non-transfected control cells were isolated and washed three times in PBS. 5x106 cells, 
in 100 µl PBS, were injected subcutaneously, into the lower right dorsal region of mice (nu/nu 
BALB/c, Tac:Cr:(NCr)-Foxn1nu, Taconic, Hudson, NY). Tumor size was measured three times a 
week, and tumor volume was calculated using the formula: [(Length x Width2)/2]. Mice were 
sacrificed by CO2 inhalation, and tumors were resected and snap-frozen in an ethanol-dry ice 
bath. 5 µm sections were prepared from O.C.T-embedded tumors, and immunohistochemistry 
was performed as described in Section 2.8.  
2.14 VECTOR CONSTRUCTS FOR IN VIVO TARGETING 
For in vivo gene-targeting experiments, two additional plasmid vectors were generated. pREP7-
RSV, an episomal expression vector, contains the Rous sarcoma virus (RSV) promoter 
(Invitrogen). pREP7-TYR, contains a 430 bp cDNA fragment of the tyrosinase promoter (TYR), 
which replaces the RSV promoter. The tyrosinase promoter mediates tissue-specific expression 
of the vector in cells of melanocytic origin (Bentley et al., 1994). Antisense (AS) and sense-
oriented vector constructs for N-cadherin, MCAM, and β3 integrin were generated using the 
sequences and methods described in Section 2.6. For sense-oriented plasmids, cDNA sequences 
were amplified using the primers described in Section 2.6, containing the appropriate restriction 
sites for subcloning in their sense orientation.  
2.15 INTRATUMORAL PLASMID INJECTIONS 
5x106 cells (WM983B) were injected subcutaneously, as described in Section 2.13. Tumor 
volume was monitored, and when the tumors reached a perpendicular diameter of approximately 
5x5 mm, intratumoral plasmid injections were initiated, and continued on a twice-weekly basis.  
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To determine the most optimal in vivo delivery strategy, several different gene delivery 
reagents were tested. In the case of Lipofectamine 2000 (Invitrogen), 50-100 µg of plasmid DNA 
was diluted in either PBS or TE pH 8.0 (10mM Tris-Cl, pH 8.0, 1 mM EDTA). 3-5 µg of 
Lipofectamine 2000 was added to the diluted DNA, and incubated for 25 minutes at room 
temperature prior to injection. For Mirus TransIT In Vivo Gene Delivery (Mirus Bio 
Corporation), 290 mM glucose, 20 µg of plasmid DNA (1 µg/µL), and 20 µL of TransIT reagent 
were mixed, vortexed, and incubated for 5 minutes at room temperature prior to injection. For 
the In vivo jetPEI reagent (Bridge Biosciences), 10 µg of plasmid DNA was diluted into 5% 
glucose to a volume of 50 µL, while 2 µL of jetPEI was diluted into 48 µL of 5% glucose. The 
jetPEI mixture was added to the diluted DNA, and incubated for 15 minutes at room temperature 
prior to injection. For Gene/NovaFECTOR reagent (Venn Nova, Inc), 25 µg of plasmid DNA 
was diluted in 50 µL of water, and 25 µL of Gene/NovaFECTOR was diluted into 25 µL of 
water, to give a final ratio of 1:1 µg of DNA:liposome. The DNA was added to the 
Gene/NovaFECTOR mixture, and incubated for 20 minutes at room temperature prior to 
injection. For injection of “naked” plasmid DNA, 50 µg of pcDNA-LacZ control plasmid was 
diluted in PBS and injected. At the completion of the experiments, tumors were extracted and 
snap-frozen. 
2.16 DNA EXTRACTION FROM MELANOMA XENOGRAFTS 
Total DNA was extracted from tumors using the DNeasy Tissue kit (Qiagen). PCR was 
performed with primers specific for each vector. The forward primers were designed to anneal to 
the promoter region of each vector - RSV promoter: 5’ GCTCGATACAATAAACGCC 3’, TYR 
promoter: 5’ CACTGTAGTAGTAGCTGG 3’, and CMV promoter: 5’ 
TAATACGACTCACTATAGGG 3’. The reverse primers were specific for the 3’ end of each 
antisense or sense-oriented cDNA insert. As a positive control, the sense or antisense cDNA was 
amplified from purified sense or antisense plasmid construct via PCR.  
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2.17 PROTEIN ISOLATION FROM MELANOMA XENOGRAFTS 
75-100 mg of frozen tumor tissue was minced and placed into 250 uL of Cell Lysis Buffer (Cell 
Signaling Technology), supplemented with 1 mM PMSF, and processed as described in Section 
2.7.  
2.18 ΒETA-GALACTOSIDASE ASSAY 
Tumors were injected with pcDNA3.1-CMV plasmid containing the LacZ reporter gene, using 
several gene delivery reagents. 48 hours later, the mice were sacrificed and their tumors snap-
frozen. 5 µm sections were prepared and processed as per the manufacturer’s instructions for the 
β-Gal Staining Kit (Invitrogen).  
2.19 TARGETING ALPHA V BETA 3 INTEGRIN THROUGH A FUNCTION-
BLOCKING ANTIBODY (ABEGRIN) 
1x105 cells were plated in 24-well culture dishes. Twenty-four hours later, 50 µg/mL (in the case 
of WM1158) or 75 µg/mL (in the case of WM983B) of Abegrin antibody (from Medimmune 
Inc., Gaithersburg, MD) diluted in PBS was added to the culture medium. At the indicated times, 
cells were detached with trypsin/EDTA, and counted using a hemacytometer. Replicate counts 
were averaged for each sample.  
WM983B cells were injected into nude mice to generate melanoma xenografts, as 
described in Section 2.13. When the tumors reached approximately 5x5 mm in perpendicular 
direction, 100 µg of Abegrin diluted in 75 µL PBS was injected directly into the tumors. The 
injections were repeated three times a week. At the completion of the experiment, tumors were 
snap-frozen as described in Section 2.13.  
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3.0  WHOLE-GENOME AND TISSUE MICROARRAY ANALYSIS DEMONSTRATE 
THAT N-CADHERIN AND ΒETA 3 INTEGRIN ARE MELANOMA PROGRESSION 
MARKERS, WHEREAS MCAM IS NOT 
3.1 INTRODUCTION 
Previous research has documented that N-cadherin, MCAM, and β3 integrin are not expressed in 
melanocytes of normal skin, but they are expressed at high levels in a substantial number of 
melanoma cell lines and tissues (Holzmann et al., 1987; Albelda et al., 1990; Hsu et al., 1996). 
However, the expression of the three adhesion molecules has never been examined in concert, 
and furthermore, this is the first study to examine the expression of these molecules through 
microarray analyses. Our whole-genome and tissue microarray analyses illustrate both mRNA 
and protein expression for N-cadherin, MCAM, and β3 integrin, during the distinct stages of 
melanoma progression. This systematic evaluation of their expression in tissues facilitates the 
determination of the specific stage of progression whereby the expression of each molecule is 
substantially increased. Second, the TMAs made it possible to examine, for the first time, the co-
expression of N-cadherin, MCAM, and β3 integrin within the same clinical specimens, thus 
answering the question, do individual metastatic melanomas express more than one of these 
adhesion molecules, or is one sufficient?  
In line with the goals described above, tissue specimens ranging from normal human skin 
all the way to melanoma-infiltrated lymph nodes were subjected to whole-genome expression 
profiling. N-cadherin, MCAM, and β3 integrin mRNA expression will be presented. Next, in 
order to examine the protein expression and localization of the three adhesion molecules, four 
separate tissue microarrays, composed of either nevi, VGP melanomas, subcutaneous and 
visceral MGP melanomas, or melanoma-infiltrated lymph nodes (LN), were probed with 
antibody specific for N-cadherin, MCAM, or β3 integrin. Together, the microarray data expand 
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upon gaps in the literature regarding the expression of N-cadherin, MCAM, and β3 integrin in the 
distinct stages of melanoma progression.  
3.2 RESULTS 
3.2.1 Whole-genome microarrays 
For the whole-genome expression profiling, biotinylated cRNAs were generated from tissue 
specimens representing normal skin, benign and atypical nevi, and early and advanced-stage 
melanomas, as well as cultured human keratinocytes, melanocytes, and human MGP melanoma 
cells, and hybridized to Affymetrix Human Genome U133 Plus 2.0 Gene Chip Arrays (Smith et 
al., 2005). Normalized signal intensity values for N-cadherin, MCAM, and β3 integrin expression 
are displayed in Figure 4. Each bar represents one tissue specimen. The microarray data reveal 
an increase in N-cadherin mRNA expression concordant with the transition from melanoma in 
situ to VGP melanoma. β3 integrin expression in the samples was lower than anticipated, 
increasing only slightly in the VGP and MGP melanomas, but highly expressed in one lymph 
node metastasis. In contrast to N-cadherin and β3 integrin, MCAM is expressed in benign and 
atypical nevi, as well as in melanomas in situ. MCAM mRNA levels are further increased in 
VGP and MGP melanomas, and in melanoma-infiltrated lymph nodes.  
The whole-genome arrays indicate that all three adhesion molecules are expressed in 
short-term cultures of melanocytes, as previously described, although melanocytes of normal 
skin do not express these molecules to a significant degree (Albelda et al., 1990; Shih et al., 
1994). This observation was expected, given that in the absence of keratinocyte-mediate growth 
control, it is well-established in the literature that cultured melanocytes begin to express 
melanoma antigens, and that cultured melanocytes do not accurately represent the phenotype of 
melanocytes of normal skin (Herlyn et al., 1987). All three cell adhesion molecules are likewise 
expressed in the MGP melanoma cell line WM1158.  
Because we only subjected one MGP melanoma cell line to whole-genome microarray 
analysis, we performed RT-PCR to determine the level of N-cadherin, MCAM, and β3 integrin 
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mRNA in additional cell lines. The expression of N-cadherin, MCAM, and β3 integrin mRNA in 
three MGP melanoma cell lines is illustrated in Figure 5. In the WM983B cells, the β3 integrin 





Figure 4: N-cadherin, MCAM, and β3 integrin mRNA expression in cells and tissues subjected to 
whole-genome expression profiling 
The samples represent short-term cultures of human keratinocytes (Ker) and neonatal melanocytes (Mel), 
and tissue specimens including normal skin (NS1; NS2), benign nevi (BN1; BN2), atypical nevi (AN1; 
AN2), melanomas in situ (in situ1; in situ2), VGP melanomas (VGP1; VGP2), MGP melanomas (MGP1; 
MGP2), melanoma-infiltrated lymph nodes (LN1; LN2; LN3), and cultured MGP melanoma cells 
(WM1158).  
 
Figure 5: N-cadherin, MCAM, and β3 integrin expression in MGP melanoma cells as determined by 
RT-PCR 
Total RNA was extracted from WM1158, WM852, and WM983B cells, and N-cadherin, MCAM, or β3 
integrin cDNA was amplified by RT-PCR. The sizes of the RT-PCR-amplified fragments are: N-cadherin 
1.9 kb, MCAM 1.8 kb, β3 integrin 2.3 kb.  
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3.2.2 Tissue microarrays 
To independently validate the whole-genome microarray data, we used tissue microarrays 
(TMAs), consisting of four individual TMAs composed of benign and atypical nevi, VGP 
melanomas, subcutaneous and visceral MGP melanomas, or melanoma-infiltrated lymph nodes 
(LN). Each TMA was probed with antibody specific for human N-cadherin, MCAM, or β3 
integrin.  
The percentage of tissue cores from each TMA exhibiting expression of each protein, or 
lack thereof, is illustrated in Table 1. We found that expression of N-cadherin and β3 integrin 
increases from nevi ? VGP ? MGP melanoma. N-cadherin is detected in 39.5% (nevi), 60.5% 
(VGP), and 65.0% (MGP) of cores, while β3 integrin is detected in 0% (nevi), 30.6% (VGP), and 
77.9% (MGP) of cores. In contrast, MCAM is expressed in a significant percentage of both VGP 
and MGP melanomas (85.7 and 77.3%), but is also expressed in 81.4% of nevi. Therefore, the 
TMA, like the whole-genome profiling data (Smith et al., 2005), do not support earlier 
suggestions that MCAM is a melanoma progression marker. In Table 2, the data are expressed as 
the average score (0-2) for each adhesion molecule, in each TMA. These data clearly confirm the 
results described in Table 1.  
It should be noted that the LN tissue cores did not yield strong/overall good quality signal 
for any of the molecules examined in the context of the TMA project. We did not observe this 
technical problem with the nevus, VGP, or MGP TMAs. Therefore, this observation is currently 










Table 1: N-cadherin, MCAM, and β3 integrin expression in melanoma progression pathway TMAs 
TMA slides were stained with N-cadherin, MCAM, or β3 integrin antibody. Antibody-probed tissue cores 
were scored using a scale of 0 (no signal), 1 (weakly positive), or 2 (strongly positive). The results are 














% scored 1 or 2 39.5 60.5 65.0 26.7 
% scored 2 2.6 9.3 10.0 10.0 
% scored 1 36.8 51.2 55.0 16.7 














% scored 1 or 2 81.4 85.7 77.3 71.4 
% scored 2 39.5 25.7 56.1 31.4 
% scored 1 41.9 60.0 21.2 40.0 















% scored 1 or 2 0 30.6 77.9 26.3 
% scored 2 0 11.1 45.6 18.4 
% scored 1 0 19.4 32.4 7.9 
% scored 0 100 69.4 22.1 73.7 
  
 
Table 2: Average scores for N-cadherin, MCAM, and β3 integrin expression in each TMA 
The data are expressed as the average score (0-2) for N-cadherin, MCAM, and β3 integrin expression, on 
each TMA 
 






VGP   
 
 
MGP   
 
LN  
N-cadherin 0.42 0.70 0.75 0.37 
MCAM 1.21 1.11 1.33 1.03 





Selected images of N-cadherin-probed TMA cores are shown in Figure 6. Overall, N-
cadherin expression was somewhat weak across the TMA slides, and we believe this may have 
been a result of the antibody dilution. However, it is clear that N-cadherin expression is weak or 
absent in nevi, and high in some, but not all, VGP and MGP melanomas.  
 
 
Figure 6: Expression of N-cadherin in melanoma progression pathway TMAs 
Tissue cores, representing nevi, VGP melanomas, MGP melanomas, and melanoma-infiltrated lymph 














Selected images of MCAM-probed TMA cores are shown in Figure 7. They represent the 
same set of tissue cores depicted in Figure 6. MCAM, unlike N-cadherin and β3 integrin, is 
expressed in most nevi. In addition to its expression in nevocytes, which are clusters of 
melanocytes, MCAM was also expressed in certain cells of the dermis, including endothelial 
cells and hair follicles (data not shown). In the majority of VGP and MGP melanoma cores, 
MCAM is expressed at high levels.  
 
 
Figure 7: Expression of MCAM in melanoma progression pathway TMAs 
Tissue cores, representing nevi, VGP melanomas, MGP melanomas, and melanoma-infiltrated lymph 







Selected images of β3 integrin-probed TMA cores are illustrated in Figure 8. The same 
corresponding tissue cores are illustrated as in Figure 6 and 7, except for the core in the upper 
right-hand corner, which was missing from the β3 integrin TMA. β3 integrin is not expressed in 
any of the nevi, but is first detected in VGP melanomas, and is highly expressed in the MGP 
melanomas. In several of the VGP and MGP melanomas, β3 integrin is also detected in blood 
vessels (Figure 9).  
 
 
Figure 8: Expression of β3 integrin in melanoma progression pathway TMAs 
Tissue cores, representing nevi, VGP melanomas, MGP melanomas, and melanoma-infiltrated lymph 




Figure 9: β3 integrin expression in melanoma-infiltrating blood vessels 
 
As a “negative” control, we probed each TMA with antibody to PERP (p53 apoptosis 
Effector Related to PMP-22 (Attardi et al., 2000), a molecule that was first identified as a tumor 
suppressor of melanoma (Hildebrandt et al., 2001), and which we have confirmed as being 
downregulated in advanced-stage melanomas (Smith et al., 2005). The absence of staining in two 
selected PERP-probed TMA cores, compared with the same cores probed for N-cadherin, 
MCAM, or β3 integrin, is illustrated in Figure 10. The results shown are representative of all 
PERP-stained TMA cores.  
 
 
Figure 10: Selected tissue cores probed with antibody to PERP, serving as a "negative" control for 
the TMA staining 
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 Given the finding that every one of the three cell adhesion molecules is expressed in 
some VGP and MGP melanomas, we next determined to what extent subcutaneous and visceral 
MGP melanoma lesions from individual patients express one, two, or all three proteins. As 
summarized in Table 3, 97% of the 59 tumors analyzed expressed at least one, 80% two, and 
48% all three. These data suggest that simultaneous expression of all three adhesion molecules 
may not be required for melanoma metastasis. However, the fact that 97% of tumors express at 
least one molecule points to a critical role of the three adhesion molecules in the process of 
metastasis formation, whereby expression of at least one of these three molecules is essential.  
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Table 3: Co-expression of N-cadherin, MCAM, and/or β3 integrin in MGP melanomas 
Fifty-nine MGP melanoma tissue cores, composed of subcutaneous and visceral metastases. Cores were 
scored on a scale of 0 (no stain), 1 (weakly positive), or 2 (highly positive).  
 
 
Level of Expression 
 
Level of Expression 
















1 2 2 2 31 1 2 0 
2 2 2 2 32 1 0 2 
3 1 2 2 33 1 2 0 
4 0 2 2 34 0 1 2 
5 2 2 1 35 1 0 2 
6 1 2 2 36 0 2 1 
7 0 2 2 37 0 1 2 
8 1 2 2 38 0 2 1 
9 1 2 2 39 0 2 1 
10 1 2 2 40 0 0 2 
11 1 2 2 41 1 0 2 
12 1 2 2 42 2 0 1 
13 1 2 2 43 1 2 0 
14 1 2 2 44 0 2 1 
15 1 2 2 45 1 0 2 
16 1 2 2 46 0 2 0 
17 1 2 2 47 2 0 0 
18 1 2 2 48 0 2 0 
19 0 2 2 49 0 0 2 
20 1 2 1 50 0 2 0 
21 1 1 2 51 1 1 1 
22 1 1 2 52 1 1 1 
23 1 2 1 53 1 1 1 
24 1 2 1 54 0 1 1 
25 1 2 1 55 0 1 0 
26 1 1 2 56 0 0 1 
27 1 2 1 57 0 0 1 
28 1 1 2 58 0 0 0 
29 2 1 0 59 0 0 0 
30 1 2 0 60 - - - 
 
 
Another question we asked with respect to the TMA data was whether expression of N-
cadherin, MCAM, and/or β3 integrin correlates with formation of metastases at a particular organ 
site. We organized the available data for the subcutaneous and visceral MGP melanoma TMA 
into four categories of organ-site of metastasis: soft tissue metastases (10), lung metastases (6), 
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subcutaneous metastases (27), and gastrointestinal metastases (12) Expression of N-cadherin, 
MCAM, and β3 integrin (scored 0, 1, or 2) in each organ site is illustrated in Figure 11. Although 
the overall number of tissue samples per group is relatively low, the data provide some insights 
correlating expression of each adhesion molecule with the site of metastasis formation. Soft 
tissue metastases show the most prominent expression of β3 integrin, while lung metastases 
exhibit high-level expression of both MCAM and β3 integrin in a significant percentage of tissue 
cores. In subcutaneous metastases, MCAM is the most highly expressed adhesion molecule, 
although N-cadherin and β3 integrin are also present in a majority of tissue specimens. 
Interestingly, 100% of the gastrointestinal metastases analyzed express β3 integrin to some 
degree. Furthermore, of the four organ-site categories, the gastrointestinal metastases were the 
most likely to co-express all three adhesion molecules (8 out of 12 cores examined - 66%).  
 
 
Figure 11: Expression of N-cadherin, MCAM, and β3 integrin in melanomas metastasized to 
different organ sites  
The data from the MGP melanoma TMA were evaluated according to metastasis to four distinct organ 
sites: soft tissue (10), lung (6), subcutaneous (27), or gastrointestinal (12). They are expressed as the 
percentage of cores in each group expressing N-cadherin, MCAM, or β3 integrin: 0 (no stain), 1 (weakly 
positive), 2 (highly positive) 
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3.3 DISCUSSION 
Our whole-genome expression profiling data, combined with the results of our TMA analysis, 
demonstrate that N-cadherin and β3 integrin are melanoma progression markers, whereas 
MCAM, despite its strong expression in advanced-stage melanomas, is not. The latter finding 
corroborates previous data, obtained in the context of a small-scale immunohistochemical 
analyses of benign and atypical nevi (Wang et al., 1996). Furthermore, we demonstrate that 80% 
of subcutaneous and visceral MGP melanoma tissue cores express at least two of the respective 
three adhesion molecules, and approximately 50% of them reveal expression of all three (Table 
1). On the one hand, this suggests that all three cell adhesion molecules need not be expressed at 
the same time in a given MGP melanoma to govern metastasis. On the other hand, given that one 
of the three adhesion molecules is nearly always present in the MGP melanomas, we postulate 
that every one of these molecules plays a role in metastasis.  
These observations are important in the context of melanoma treatment. If all three 
adhesion molecules are essential for metastasis, then blocking one should, in theory, suffice to 
inhibit metastasis. However, the TMA data suggest that, in fact, melanomas can metastasize 
without expressing all three molecules. The fact that each adhesion molecule is not essential 
suggests that it may be necessary to simultaneously target more than one adhesion molecule for 
the most effective treatment. This strategy may be of particular importance in patients who co-
express the molecules – in these patients, upon blocking one adhesion molecule, another may 
compensate for its function, rendering the therapy ineffective. Furthermore, and equally 
important, the whole-genome and TMA data demonstrate that expression profiles vary in 
melanomas from patient-to-patient, which should be taken into consideration when determining 
the most effective therapeutic strategy for individual patients. Finally, our data raise the 
important question, are advanced-stage melanomas that express all three molecules more 
aggressive with respect to metastasis formation at distant sites than the ones expressing only one 
or two molecules? This important aspect will be further addressed in our overall discussion.  
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4.0  INHIBITION OF N-CADHERIN, MCAM, OR ΒETA 3 INTEGRIN REDUCES 
PROLIFERATION OF HUMAN MGP MELANOMA CELLS  
4.1 INTRODUCTION 
Following the whole-genome and TMA analysis, our next objective was to investigate the 
functional role of N-cadherin, MCAM, and β3 integrin in human MGP melanoma cells. To 
obtain information regarding the biological function(s) of each of the three molecules in 
advanced-stage melanomas, the first question we asked was, do these genes play a role in 
melanoma cell proliferation? Previous literature has suggested an association of these adhesion 
molecules with signaling pathways and genes that regulate proliferation and survival, such as 
bFGF/FGFR-1 (Suyama et al., 2002; Sahni and Francis, 2004) and Akt (Zheng et al., 2000; Li et 
al., 2001; Tran et al., 2002; Li et al., 2003). However, studies examining the effect upon 
proliferation following inhibition of the endogenous molecules in melanoma cells are lacking. 
We hypothesized that inhibiting N-cadherin, MCAM, or β3 integrin expression may decrease 
melanoma cell proliferation. In addition, we tested whether blocking expression of all three 
molecules in concert would result in a greater decrease in proliferation compared with their 
individual inhibition. We used two experimental approaches – RNA interference (RNAi) and 
antisense targeting - to analyze the effect on melanoma cell proliferation following inhibition of 
N-cadherin, MCAM, and/or β3 integrin.  
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4.2 RESULTS 
4.2.1 RNA interference 
RNA interference (RNAi) is a conserved biological mechanism, whereby fragments of double-
stranded RNA are processed into 20-25 nucleotide fragments by an enzyme called Dicer. 
Subsequently, the RNA fragments assemble into an RNA-induced signaling complex (RISC), 
which targets the complementary mRNA for cleavage and degradation. Small interfering RNAs 
(siRNAs) are short double-stranded RNAs, usually 19-22 nucleotides in length, which can be 
synthesized for inhibition of a specific gene in vitro. We will also demonstrate that multiple 
siRNAs can be utilized in order to simultaneously downregulate the expression of more than one 
gene.  
4.2.1.1 Downregulation of N-cadherin, MCAM, and/or β3 integrin expression in MGP 
melanoma cells by siRNA(s) 
 
siRNAs were designed to target human N-cadherin, MCAM, or β3 integrin. Two MGP 
melanoma cell lines (WM1158 and WM852) were transfected with N-cadherin, MCAM, or β3 
integrin-specific siRNA. In order to examine the transfection efficiency, each siRNA was labeled 
with the Cy3 fluorochrome, and subsequently transfected into WM1158 cells. The inset in Figure 
12 depicts Cy3-labeled siRNA taken up by the cells (pseudocolored yellow), with fluorescent 
DAPI nuclear counterstain (pseudocolored blue). The majority of the cells contained multiple 
copies of siRNA. Immunofluorescence staining indicated that the levels of N-cadherin, MCAM, 
and β3 integrin are reduced following transfection with each respective siRNA (Figure 12). 
Immunoblot analysis further demonstrated that N-cadherin, MCAM, and β3 integrin protein 
levels are decreased in both WM1158 and WM852 cells, 48 hours after treatment with each 
respective siRNA (+), compared with Lipofectamine 2000 only-transfected control cells (-) 
(Figure 13).  
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Figure 12: siRNA-mediated inhibition of N-cadherin, MCAM, or β3 integrin expression 
Fluorescence images of WM1158 melanoma cells not transfected (-), or transfected (+) with N-cadherin, 
MCAM, or β3 integrin siRNA, 72 hours post-transfection. Cells were probed with antibody to N-cadherin 
(pseudocolored red), MCAM (pseudocolored green), or β3 integrin (pseudocolored orange), followed by 
Cy5-labeled secondary antibody. Nuclei are counterstained with fluorescent DAPI (pseudocolored blue). 
Insets illustrate cells transfected with Cy3-labeled siRNA (pseudocolored yellow) to N-cadherin, MCAM, 




Figure 13: siRNA-mediated inhibition of N-cadherin, MCAM, or β3 integrin expression 
Immunoblot analysis of MGP melanoma cell lines, WM1158 and WM852, in the absence (-) or presence 
of 100 nM siRNA (+) targeting N-cadherin, MCAM, or β3 integrin, 48 hours following siRNA 
transfection.  
 
In order to address our hypothesis that simultaneous inhibition of all three adhesion 
molecules may have a more pronounced effect upon melanoma cell proliferation, we wanted to 
establish a method for inhibiting expression of all three genes at the same time. Once we had 
demonstrated successful downregulation of N-cadherin, MCAM, and β3 integrin using siRNA to 
each molecule, the next step was to attempt to simultaneously inhibit N-cadherin, MCAM, and 
β3 integrin expression using a combination of all three siRNAs. Figure 14 illustrates that the 
levels of each respective protein are decreased following combined targeting of all three 
adhesion molecules (+), compared with Lipofectamine 2000 only (-).  
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Figure 14: Combined inhibition of N-cadherin, MCAM, and β3 integrin expression through siRNA 
N-cadherin, MCAM, or β3 integrin expression in WM1158 and WM852 MGP melanoma cells in the 
absence (-), or presence (+) of a combination of 100 nM each of N-cadherin, MCAM, and β3 integrin 
siRNA, 48 hours post-transfection  
4.2.1.2  Inhibition of N-cadherin, MCAM, and/or β3 integrin expression through siRNA 
slows melanoma cell proliferation, but does not arrest it  
 
Having shown that siRNAs are an effective tool to downregulate expression of the three 
adhesion molecules, we next determined the impact on melanoma cell proliferation following 
siRNA-mediated inhibition of N-cadherin, MCAM, and/or β3 integrin. Melanoma cells were 
plated in triplicate and counted at 24, 48, and 72 hours after siRNA transfection. At the first two 
time points, we did not observe noticeable differences in the rate of proliferation of the siRNA-
transfected cells compared to controls (with the exception of β3 integrin siRNA-treated cells at 
48 hours). However, at 72 hours following siRNA-transfection, proliferation was decreased by 
approximately 50% in the cells that received N-cadherin, MCAM, and/or β3 integrin siRNA 
(Figure 15). Interestingly, this reduction in proliferation was not augmented by inhibiting, in 
parallel, the expression of all three genes.  
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Figure 15: Proliferation of melanoma cells is decreased when expression of N-cadherin, MCAM, 
and/or β3 integrin is inhibited through siRNA 
WM1158 cells were transfected with 100 nM of N-cadherin, MCAM, or β3 integrin siRNA, or a 
combination of 100 nM of each siRNA. At 24, 48, and 72 hours post-transfection, cells were counted 
using a hemacytometer. The data are expressed as the average of triplicate counts. * = p < 0.05, Student’s 
t-test 
 
Because of the noted decrease in proliferation, we next asked whether there is a link 
between inhibition of proliferation and onset of apoptosis in the MGP melanoma cells. The cell 
morphology following siRNA treatment did not provide an indication that apoptosis was 
occurring (data not shown). However, to obtain a more definitive answer to this question, we 
analyzed the siRNA-treated cells for apoptosis, using the terminal transferase dUTP nick end 
labeling (TUNEL) method, which is designed to recognize DNA strand breaks through labeling 
of free 3’OH groups. TUNEL staining was performed 72 hours following siRNA transfection, 
the same timepoint at which proliferation was significantly decreased. Consistent with our 
observations of cell morphology, cells treated with N-cadherin, MCAM, or β3 integrin siRNA, or 
a combination of all three siRNAs, did not display increased apoptosis compared with non-
transfected or Lipofectamine 2000 only-treated cells (Figure 16).  
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Figure 16: Absence of apoptosis following inhibition of N-cadherin, MCAM, and/or β3 integrin 
WM1158 or WM983B cells were transfected with 100 nM of N-cadherin, MCAM, or β3 integrin siRNA, 
or with a combination of 100 nM each siRNA (combined siRNAs). Controls were not transfected, 
transfected with Lipofectamine alone, or transfected with GFP siRNA. TUNEL assay was performed 72 
hours following siRNA transfection. Positive control cells were pre-treated with DNase I. Green 
pseudocolor indicates the presence of DNA strand breaks. The cells were not counterstained.  
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4.2.2 Antisense targeting  
The inhibition of gene expression via siRNA is transient. In contrast, vectors containing 
antisense cDNA sequences can mediate stable downregulation of expression, when transfected 
cells are grown in the presence of a selective antibiotic. Thus, we utilized this technique to 
further investigate the functional consequence of stably downregulating expression of N-
cadherin, MCAM, or β3 integrin in an MGP melanoma cell line.  
4.2.2.1 Reduced expression of N-cadherin, MCAM, and β3 integrin in antisense-transfected 
cells 
 
In parallel with the siRNA targeting approach, we generated pcDNA3.1 expression vectors 
containing antisense-oriented N-cadherin, MCAM, or β3 integrin cDNA, driven by a CMV 
promoter. Each plasmid vector was transfected into WM983B MGP melanoma cells, as 
described in the Materials and Methods section. Transfectants were selected in the presence of 
hygromycin, the antibiotic marker contained in the pcDNA3.1 vector, and screened for protein 
expression. Illustrated in Figure 17 are three cell lines that stably express N-cadherin, MCAM, or 
β3 integrin antisense plasmid and show reduced levels of each respective protein. Therefore, both 
siRNA and antisense plasmid vectors successfully downregulated expression of the adhesion 
molecules in MGP melanoma cells.  
 
Figure 17: N-cadherin, MCAM, and β3 integrin antisense-transfected cells 
WM983B cells were transfected with pcDNA vector only, or with pcDNA vector containing antisense-
oriented cDNA for N-cadherin, MCAM, or β3 integrin. Hygromycin-resistant colonies were propagated. 
Whole-cell lysates were collected and analyzed by immunoblot analysis for expression of N-cadherin, 
MCAM, or β3 integrin. Actin serves as a loading control.  
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4.2.2.2 N-cadherin and β3 integrin antisense-transfected cells display altered morphology 
 
Phase-contrast images were acquired of the antisense-transfected N-cadherin, MCAM, and β3 
integrin cell lines and depicted in Figure 18. In the N-cadherin antisense transfectants, about 50% 
of the cells exhibit a more rounded, epithelial morphology, compared with the fibroblastic 
morphology of control non-transfected or vector only-transfected cells. This fact is intriguing, 
considering that E-cadherin is generally expressed in epithelial cell types, while N-cadherin 
expression is associated with mesenchymal cells. The MCAM antisense cells, on the other hand, 
show no substantial alterations in morphology compared with controls. The β3 integrin antisense 
cells, however, tend to grow more in clusters or groups of cells, rather than in a uniform sheet 
across the surface of the culture dish. This suggests that there is an impact upon adhesion of the 
melanoma cells to the matrix following downregulation of β3 integrin expression.  
In the case of the N-cadherin, MCAM, and/or β3 integrin siRNA-transfected cells, no 
significant changes in morphology were observed up to 72 hours following transfection (data not 
shown). However, it is important to note that the transient inhibition of expression following 
siRNA transfection may yield a less pronounced effect upon morphology compared with a stable 
downregulation of expression by means of an antisense plasmid.  
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Figure 18: Morphology of antisense-transfected cells 
Phase-contrast images of cultured cells, at 10X magnification.  
4.2.2.3 Proliferation of MCAM and β3 integrin antisense-transfected cells is impaired, but 
not arrested 
 
We next determined the rate of proliferation of the N-cadherin, MCAM, and β3 integrin antisense 
transfectants in comparison to non-transfected or pcDNA vector only-transfected cells. The cells 
were plated in 96-well culture dishes, and the MTT colorimetric assay was performed at the 
indicated timepoints. Similar to the MCAM and β3 integrin siRNA transfected cells, the MCAM 
and β3 integrin antisense transfectants demonstrated a 30-40% lower growth rate compared to the 
controls (Figure 19). However, proliferation of the N-cadherin antisense transfectants did not 
differ from the controls.  
The different effect upon proliferation following inhibition of N-cadherin through siRNA 
compared with antisense targeting could be a result of several factors. First, siRNA and 
antisense-mediated inhibition may elicit somewhat different cellular responses, due to their 
different mechanism of inhibition. Furthermore, the siRNA inhibition is transient, whereas the 
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stable antisense-mediated downregulation is maintained long-term. Second, the two MGP 
melanoma cell lines utilized for the experiment (WM1158 versus WM983B) may respond 
differently to the inhibition of N-cadherin. In the future, it would be valuable to generate 
WM1158 cells that stably express antisense N-cadherin, MCAM, or β3 integrin vector. Overall, 
however, the trend toward decreased proliferation following inhibition of the three cell adhesion 
molecules is similar with both experimental approaches.  
 
 
Figure 19: Proliferation of melanoma cells is decreased when expression of MCAM or β3 integrin is 
downregulated via pcDNA antisense plasmid 
The MTT assay was performed at timepoints following plating of each cell lines in 96-well culture dishes 
(* = p < 0.05, Student’s t-test).  
4.3 DISCUSSION 
To address the question of whether N-cadherin, MCAM, and/or β3 integrin play a role in 
melanoma cell proliferation, RNAi and antisense targeting were used to downregulate expression 
of each gene in MGP melanoma cells. Furthermore, we simultaneously inhibited expression of 
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all three adhesion molecules using a combination of all three siRNAs. Whereas morphological 
differences were not observed following transfection with siRNAs, the N-cadherin and β3 
integrin stable antisense transfectants display altered morphology, suggesting changes in the 
adhesion properties of these cells.  
siRNA-mediated inhibition of N-cadherin, MCAM, or β3 integrin led to a 50% decrease 
in melanoma cell proliferation. Simultaneous inhibition of N-cadherin, MCAM, and β3 integrin 
did not augment this effect. In the case of the MCAM and β3 integrin antisense transfectants, 
proliferation was decreased by approximately 30-40%, but proliferation of N-cadherin antisense 
cells was not significantly altered. Again, it is likely that this discrepancy is due in part to the 
different methodological approach – in particular, the fact that siRNA-mediated inhibition is 
transient, while the antisense approach we utilized is maintained long-term.  
Although a decrease in proliferation was observed as indicated, the fact that it was 
possible to propagate colonies stably expressing N-cadherin, MCAM, or β3 integrin antisense 
plasmid was a preliminary indication that proliferation was not completely arrested. Neither cell 
morphology nor TUNEL staining of the siRNA-transfected cells compared to the two controls 
provided evidence that the decrease in proliferation was accompanied by onset of melanoma cell 
apoptosis. Therefore, the data support the hypothesis we put forward that inhibition of N-
cadherin, MCAM, and/or β3 integrin partially impairs MGP melanoma cell proliferation. 
However, when compared to the results of targeting basic fibroblast growth factor (bFGF; FGF2) 
and/or FGFR-1, which both in vitro and in vivo, lead to complete arrest of melanoma growth 
(Wang and Becker, 1997), the data presented here do not make an overly strong argument for N-
cadherin, MCAM, and/or β3 integrin being absolutely essential for melanoma cell proliferation.  
The residual growth of the MGP melanoma cells is likely maintained through alternative 
signaling pathways. In epithelial cells (MDCK), for example, although the cells undergo anoikis 
following disruption of cell-ECM interactions, overexpression of bcl-2 can rescue the cells from 
apoptosis, as can transformation with the v-src oncogene, or treatment with scatter factor/HGF 
(Frisch and Francis, 1994). In melanoma cells, bFGF (Becker et al., 1992) and pAkt (Dai et al., 
2005), to name a few, have been implicated in melanoma progression, and may mediate, to some 
degree, cell proliferation and anti-apoptotic signaling in the absence of N-cadherin, MCAM, 
and/or β3 integrin expression.  
 53 
Overall, the results demonstrate that N-cadherin, MCAM, and β3 integrin partially 
mediate melanoma cell proliferation, but that blocking their expression does not fully arrest 
proliferation, and does not drive the cells into apoptosis. Although N-cadherin, MCAM, and β3 
integrin play a role in melanoma cell proliferation, they may not represent the primary mediators 
of proliferation.  
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5.0  INHIBITION OF N-CADHERIN, MCAM, AND/OR ΒETA 3 INTEGRIN 
EXPRESSION DOES NOT CAUSE DEREGULATION OF RELATED MOLECULES 
5.1 INTRODUCTION 
In light of the observed effect upon proliferation following inhibition of N-cadherin, MCAM 
and/or β3 integrin, we next addressed the questions; what signaling pathways are altered in these 
MGP melanoma cells? Is the expression of other adhesion molecules impacted? Three major 
pathways were investigated following inhibition of N-cadherin, MCAM, and/or β3 integrin: the 
putative reciprocal relationship between N-cadherin and E-cadherin, the expression of the αv 
integrin subunit, and the Akt signaling pathway.  
In the case of E-cadherin, there is a well-established switch from E to N-cadherin 
expression in numerous cancers of epithelial origin (for review, see Cavallaro, 2004), including 
melanoma (Hsu et al., 1996). As described in the introduction, re-expression of E-cadherin in a 
melanoma cell line results in decreased invasion and tumor formation (Hsu et al., 2000). 
However, to date, it is unknown whether E-cadherin expression can be restored in melanoma 
cells following inhibition of N-cadherin expression. Antisense-mediated downregulation of N-
cadherin in a squamous cell carcinoma cell line suggested that in some cell types, E-cadherin 
expression might be restored via this approach (Islam et al., 1996). This question is intriguing, 
given that E-cadherin-mediated interactions between melanocytes and keratinocytes help to keep 
melanocyte proliferation in check (Valyi-Nagy et al., 1993). Re-expression of E-cadherin in 
melanoma cells might therefore result in decreased melanoma cell proliferation.  
The αv integrin subunit, which associates with the β3 integrin subunit, represents another 
relevant molecule for investigation. Expression of the αvβ3 integrin complex increases 
concordant with melanoma progression (Natali et al., 1997); yet, expression of the αv integrin 
subunit remains unchanged (Albelda et al., 1990). The αv integrin subunit can also associate with 
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other β subunits, including β1 (Bodary and McLean, 1990), and β5 (Smith et al., 1990). We 
examined whether αv integrin expression is altered following downregulation of β3 integrin.  
Akt is known to promote survival/proliferation in many human cancers, including 
melanoma (for review, see Vivanco and Sawyers, 2002). There have been several reports in the 
literature linking the expression of N-cadherin, MCAM, and β3 integrin with Akt signaling. For 
example, in two melanoma cell lines, an N-cadherin function-blocking antibody was shown to 
inhibit the phosphorylation (activation) of Akt (Li et al., 2001). Also, transfection of additional 
copies of MCAM into a melanoma cell line lead to phosphorylation of Akt, while expression of a 
constitutively active Akt also increases MCAM expression (Li et al., 2003). This study generated 
some uncertainty as to whether Akt acts as an upstream regulator or a downstream “effector” of 
MCAM in melanoma cells, or whether a reciprocal relationship exists. A link between the 
engagement of αvβ3 integrin through vitronectin and/or osteopontin and the activation of Akt has 
been demonstrated in prostate carcinoma cells (Zheng et al., 2000). Most of these studies utilized 
antibodies that block protein function, and none addressed the consequence of inhibiting of N-
cadherin, MCAM, or β3 integrin mRNA/protein expression in melanoma cells. We examined the 
phosphorylation of Akt at Serine 473 following inhibition of these molecules by way of siRNA 
or stable antisense inhibition. Activation of Akt requires phosphorylation at two sites 
(Threonine308 and Serine473), with phosphorylation at Serine473 required for complete 
activation. The goal of our approach was to determine whether the observed decrease in 
proliferation following inhibition of N-cadherin, MCAM, and/or β3 integrin was accompanied by 
changes in Akt activation.  
Finally, the hypothesis that inhibition of one adhesion molecule might lead to a 
compensatory change in expression of the other adhesion molecules was addressed, by 
examining whether individual inhibition of N-cadherin, MCAM, or β3 integrin leads to changes 
in expression of the remaining two molecules. Because N-cadherin, MCAM, and β3 integrin are 
reported to perform overlapping functions in the melanoma cells, an increase in the expression of 
another adhesion molecule might indicate that it is compensating for the function of the 
downregulated molecule. In the development of future therapeutic approaches, this issue will be 
crucial, because a drug designed to block expression of one adhesion molecule may not generate 




5.2.1 Expression of related molecules following inhibition of N-cadherin, MCAM, and/or 
β3 integrin through siRNA 
Because E-cadherin expression is decreased concordant with melanoma progression, while N-
cadherin expression is upregulated (Tang et al., 1994; Danen et al., 1996; Hsu et al., 1996), we 
investigated whether blocking N-cadherin would result in re-expression of E-cadherin in two 
MGP melanoma cell lines that no longer express E-cadherin. Upon inhibition of N-cadherin by 
RNAi, E-cadherin expression is not restored (Figure 20) (MCF-7 cells were used as a positive 
control for efficacy of the E-cadherin antibody). This result is in contrast to a previous study 
examining a squamous cell carcinoma cell line, whereby antisense-mediated downregulation of 
N-cadherin did, in fact, lead to restored expression of E-cadherin (Islam et al., 1996). Next, we 
demonstrated that following inhibition of β3 integrin, expression of the αv integrin subunit, which 
associates non-covalently with the β3 subunit, was unchanged (Figure 22). This result suggests 
that αv integrin is likely associating with an alternative beta subunit in the absence of β3 integrin.  
Due to the observed decrease in proliferation following siRNA transfection, as well as 
previous literature linking N-cadherin, MCAM, and β3 integrin with Akt signaling (Zheng et al., 
2000; Li et al., 2001; Li et al., 2003), we investigated whether Akt phosphorylation was altered 
in siRNA-treated melanoma cells. In melanoma cells transfected with Lipofectamine 2000 only, 
immunoblotting shows that Akt is phosphorylated at serine 473. However, following siRNA 
treatment, there is no change in the level of Ser473-phosphorylated Akt protein at 48 (data not 
shown) or 72 hours post-transfection (Figure 23), despite the decrease in proliferation previously 
indicated at 72 hours. Therefore, the observed decrease in proliferation is not a consequence of 
inhibition of Akt phosphorylation.  
Finally, we determined whether siRNA-mediated inhibition of N-cadherin, MCAM, or β3 
integrin would increase or decrease the protein levels of one another. Western blotting 
demonstrated that upon inhibition of N-cadherin, MCAM, or β3 integrin, there is no substantial 
change in the protein levels of the other two molecules (Figures 20-22).  
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Figure 20: siRNA-induced inhibition of N-cadherin expression does not lead to changes 
in levels of MCAM, β3 integrin, or E-cadherin protein 
WM1158 or WM852 cells were transfected with 100 nM of N-cadherin siRNA (+), or treated with 
Lipofectamine only (-). Cell lysates were prepared at 48 hours post-transfection, and expression of 
MCAM, β3 integrin, E-cadherin, and actin was analyzed by immunoblots.  
 
Figure 21: siRNA-induced inhibition of MCAM expression does not lead to changes in levels of N-
cadherin or β3 integrin protein 
WM1158 or WM852 cells were transfected with 100 nM of MCAM siRNA (+), or treated with 
Lipofectamine only (-). Cell lysates were prepared at 48 hours post-transfection, and expression of N-
cadherin, β3 integrin, and actin was analyzed by immunoblots.  
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Figure 22: siRNA-induced inhibition of β3 integrin expression does not lead to changes in levels of 
N-cadherin, MCAM, or the αv integrin subunit  
WM1158 or WM852 cells were transfected with 100 nM of β3 integrin siRNA (+), or treated with 
Lipofectamine only (-). Cell lysates were prepared at 48 hours post-transfection, and expression of N-
cadherin, MCAM, αv integrin, and actin was analyzed by immunoblots.  
 
Figure 23: Inhibition of N-cadherin, MCAM, and/or β3 integrin expression does not alter levels of 
phosphorylated Akt, as documented at 72 hours post siRNA transfection   
WM1158 cells were transfected with 100 nM of N-cadherin, MCAM, or β3 integrin siRNA, or with a 
combination of 100 nM of each siRNA (combined siRNAs). 72 hours following siRNA transfection, cell 
lysates were prepared, and expression of pAkt (Ser473) was determined by immunoblot analysis. Actin 
serves as a loading control.   
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5.2.2 Expression of related molecules following antisense-mediated inhibition of N-
cadherin, MCAM, and/or β3 integrin  
Because siRNA exerts only a transitory effect upon inhibition of gene expression, we deemed it 
important to also assess expression patterns in the stable antisense-transfected cells. Therefore, 
the WM983B N-cadherin, MCAM, and β3 integrin antisense transfectants were analyzed for the 
same pathways described following siRNA-mediated inhibition. E-cadherin expression was not 
restored in the transfected cells following stable downregulation of N-cadherin. Nor were levels 
of the αv integrin protein substantially altered in cells following stable downregulation of β3 
integrin. Furthermore, levels of phosphorylated Akt protein were found to be unchanged 
following stable downregulation of N-cadherin, MCAM, or β3 integrin in these melanoma cells 
(Figure 24). These results were consistent with the results obtained following the inhibition of N-
cadherin, MCAM, or β3 integrin through siRNA, in two different melanoma cell lines.  
Next, we investigated whether stable antisense-mediated downregulation of N-cadherin, 
MCAM, or β3 integrin expression deregulates the protein levels of one another. In the MCAM 
antisense-transfected MGP melanoma cells, N-cadherin expression was increased by 
approximately 100%, or 2-fold, while the level of β3 integrin was reduced by approximately 75% 
(ImageJ Densitometry). In addition, in the β3 integrin antisense-transfected cells, levels of N-
cadherin were decreased by 30% (Figure 24). This result demonstrates that following stable 
downregulation of N-cadherin, MCAM, or β3 integrin, either increases or decreases in the protein 
levels of the other two adhesion molecules can occur.  
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Figure 24: Expression analysis of N-cadherin, MCAM, and β3 integrin MGP melanoma antisense 
transfectants  
MGP melanoma cells transfected with pcDNA vector only, or pcDNA vector containing N-cadherin, 
MCAM, or β3 integrin antisense-oriented cDNA, were analyzed for expression of N-cadherin, MCAM, β3 
integrin, E-cadherin, αν integrin, or p-Akt by immunoblots.  
5.3 DISCUSSION 
To assess the potential impact of inhibiting expression of N-cadherin, MCAM, or β3 integrin on 
genes/pathways potentially linked with these three molecules, we first asked the question; does 
E-cadherin become re-expressed as a result of N-cadherin downregulation? The answer was a 
clear no. E-cadherin expression is not restored; neither in the two MGP melanoma cell lines 
transfected with N-cadherin siRNA (Figure 20), nor in the N-cadherin antisense transfectants 
(Figure 24). Therefore, our findings clearly demonstrate that in melanoma cells, a direct 
reciprocal relationship between expression of E-cadherin and N-cadherin does not exist. In other 
words, unlike in squamous carcinoma cells (Islam et al., 1996), it is not possible restore E-
cadherin expression by blocking expression of N-cadherin alone. This observation is significant 
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because studies of melanocyte-keratinocyte interactions have suggested that E-cadherin plays a 
key role in regulating melanocyte proliferation (Valyi-Nagy et al., 1993). As such, the continued 
absence of E-cadherin expression in melanoma cells may contribute to the promotion of 
melanoma cell proliferation.  
The αv integrin subunit has been shown to associate with β3, β5, or β1 (Bodary and 
McLean, 1990; Smith et al., 1990; Cheresh, 1991). Neither the β3 integrin siRNA-transfected 
MGP melanoma cells (Figure 22) nor the β3 integrin antisense transfectants (Figure 24) exhibited 
a change in level of expression of the αv integrin subunit. One possible explanation for this 
observation is that αv integrin associates with β1 or β5 following downregulation of β3 integrin; 
however, we have not tested this hypothesis to date.  
As described above, several studies have suggested a link between N-cadherin, MCAM, 
and β3 integrin, and Akt activation in normal and malignant cells (Zheng et al., 2000; Li et al., 
2001; Tran et al., 2002; Li et al., 2003). Akt signaling, which is highly active in many tumors, 
can mediate proliferation, as well as anti-apoptotic signaling (reviewed by Vivanco and Sawyers, 
2002). Serine 473-phosphorylated Akt is present in control MGP melanoma cells, but protein 
levels are unchanged following inhibition of N-cadherin, MCAM, and/or β3 integrin through 
siRNA (Figure 23). Levels of Serine 473-phosphorylated Akt are also unchanged in the 
antisense-transfected melanoma cells (Figure 24). These results show that following inhibition of 
N-cadherin, MCAM, and/or β3 integrin expression, we do not observe an inhibition of Akt 
phosphorylation/signaling. This observation may explain, in part, the lack of complete arrest of 
proliferation following inhibition of these molecules, as well as the lack of onset of melanoma 
cell apoptosis. Overall, our studies suggest that in the case of MGP melanoma cells, Akt does not 
represent a direct downstream target or effecter of N-cadherin, MCAM, or β3 integrin. However, 
our results do not preclude the possibility that Akt might act as an upstream regulator of N-
cadherin, MCAM, and/or β3 integrin, which we did not investigate.  
Finally, the potential for compensatory up/down-regulation of N-cadherin, MCAM, or β3 
integrin following individual targeting was examined. Upregulation of N-cadherin, MCAM, or 
β3 integrin protein following inhibition of either alone was not detected in siRNA-treated cells 
(Figure 20-22). On the other hand, in the antisense-transfected melanoma cell lines, where 
inhibition of expression was stable and prolonged, MCAM antisense cells displayed increased 
levels of N-cadherin and decreased β3 integrin, while β3 integrin antisense cells had moderately 
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decreased levels of N-cadherin (Figure 24). The increased levels of N-cadherin in the MCAM 
antisense-transfected cells may indicate that the cells upregulate N-cadherin in order to 
compensate for the absence of MCAM. However, it is evident that expression of another 
molecule may either increase or decrease following inhibition of an individual adhesion 
molecule. This result suggests that there is some degree of interplay between expression of the 
three adhesion molecules, and it will be important to consider these mechanisms when 
developing therapeutic approaches and predicting how patient populations may respond to a 
given drug. 
Overall, it is clear from these studies that upregulation of E-cadherin or αv integrin does 
not occur following inhibition of N-cadherin or β3 integrin, respectively, and that Akt 
phosphorylation is not perturbed following inhibition of one or all three of the adhesion 
molecules examined. Our results also provide a preliminary indication that, in some cases, the 
inhibition of expression of N-cadherin, MCAM, or β3 integrin may result in a change in the 
protein levels of one another.  
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6.0  SIMULTANEOUS INHIBITION OF N-CADHERIN, MCAM, AND ΒETA 3 
INTEGRIN IMPAIRS MELANOMA CELL MIGRATION AND INVASION 
6.1 INTRODUCTION 
Migration and invasion are crucial features of cancer metastasis, and cell adhesion molecules are 
essential for these processes. Not only do they mediate interactions between the tumor cells, but 
they also govern important interactions with cells of the tumor’s microenvironment. Changes in 
the profile of adhesion molecules expressed by tumor cells can enable them to survive, migrate, 
and invade in foreign environments.  
Previous data in the literature demonstrated a pivotal role for N-cadherin, MCAM, and β3 
integrin in migration and invasion. However, knowledge regarding the impact on 
migration/invasion following inhibition of N-cadherin, MCAM, and/or β3 integrin in MGP 
melanomas is lacking. Moreover, our TMA analysis demonstrated that 97% of subcutaneous and 
visceral melanoma metastases express at least one of these three adhesion molecules, in direct 
contrast to their normal melanocyte counterparts, which do not express N-cadherin, MCAM, or 
β3 integrin (Albelda et al., 1990; Shih et al., 1994; Hsu et al., 1996). The TMA data, therefore, 
strongly suggest that N-cadherin, MCAM, and/or β3 integrin expression might play a role in 
migration and/or invasion, two key properties in the acquisition of metastatic potential.  
We hypothesized that inhibition of N-cadherin, MCAM, or β3 integrin may decrease 
melanoma cell migration/invasion, and further predicted that simultaneous inhibition of all three 
molecules may elicit an even greater response. Thus, we conducted a series of in vitro studies to 
evaluate whether N-cadherin, MCAM, and/or β3 integrin mediate melanoma cell migration 
and/or invasion.  
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6.2 RESULTS 
6.2.1 Migration is decreased in melanoma cells following transfection with either MCAM 
siRNA, or with a combination of N-cadherin, MCAM, and β3 integrin siRNAs  
To analyze cell migration, melanoma cells were transfected with N-cadherin, MCAM, or β3 
integrin siRNA, or a combination of all three siRNAs. 48 hours post-transfection, cells were 
seeded into transwell migration chambers and allowed to migrate for 22 hours, with 5% FBS 
serving as a chemoattractant. Migration of cells treated with MCAM siRNA or a combination of 
N-cadherin MCAM, and β3 integrin siRNA was reduced by 30 and 50%, respectively, in 
comparison to cells transfected with only Lipofectamine 2000 or with a scrambled siRNA 
control (Figure 25). Individual inhibition of N-cadherin or β3 integrin expression, on the other 
hand, did not result in a significant change in cell migration.  
 
Figure 25: Transfection of MGP melanoma cells with MCAM siRNA, or a combination of N-
cadherin, MCAM, and β3 integrin siRNAs leads to a decrease in migration  
WM1158 cells were transfected with Lipofectamine 2000 alone (control), 100 nM of a scrambled siRNA, 
100 nM of siRNA specific for N-cadherin, MCAM, or β3 integrin, or a combination of 100 nM each of N-
cadherin, MCAM, and β3 integrin siRNA. 48 hrs following siRNA-transfection, cells were plated in 
transwell migration chambers. Cells that migrated to the lower membrane surface were fixed, stained, and 
counted. Data are expressed as the average number of cells per 40X field that migrated to the lower 
surface of the filter. (* = p < 0.05, Student’s t-test) 
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6.2.2 Invasion is decreased in melanoma cells following transfection with MCAM siRNA, 
β3 integrin siRNA, or a combination of N-cadherin, MCAM, and β3 integrin siRNAs 
In addition to examining the impact of inhibiting N-cadherin, MCAM, and/or β3 integrin upon 
melanoma cell migration, we sought to examine whether N-cadherin, MCAM, and/or β3 integrin 
play a role in melanoma cell invasion. For analysis of invasion, the cells were plated into 
transwell chambers containing Matrigel-coated filters. Downregulation of MCAM, β3 integrin, or 
all three genes at once, through siRNA, reduced invasion by 30, 34, and 50%, respectively 
(Figure 26). In contrast, melanoma cells did not demonstrate a major change in their ability to 
invade when transfected with N-cadherin siRNA alone.  
 
 
Figure 26: Transfection of MGP melanoma cells with MCAM siRNA, β3 integrin siRNA, or a 
combination of N-cadherin, MCAM, and β3 integrin siRNAs results in decreased invasion 
WM1158 cells received Lipofectamine 2000 alone (control), 100 nM of a scrambled siRNA, 100 nM of 
siRNA specific for N-cadherin, MCAM, or β3 integrin, or a combination of 100 nM each of N-cadherin, 
MCAM, and β3 integrin siRNA. 48 hrs following siRNA-transfection, cells were plated in transwell 
migration chambers containing a Matrigel-coated filter. Cells that invaded to the lower membrane surface 
were fixed, stained, and counted. Data are expressed as the average number of cells per 40X field that 
invaded through to the lower surface of the filter. (* = p < 0.05, Student’s t-test) 
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6.3 DISCUSSION 
The results of both the migration and invasion assays confirm that simultaneous inhibition of N-
cadherin, MCAM, and β3 integrin leads to a substantially greater decrease in cell migration and 
invasion compared to targeting the molecules individually. Inhibition of N-cadherin, in fact, did 
not inhibit migration or invasion to any significant degree. On the other hand, blocking the 
expression of MCAM or β3 integrin did have a substantial impact on these two interlinked 
biological processes, which suggests that these two adhesion molecules play a role in melanoma 
cell migration and invasion.  
It is important to note, however, that although inhibition of N-cadherin did not impair 
migration/invasion, we cannot rule out the possibility that N-cadherin plays some role in these 
processes. For instance, inhibiting expression of N-cadherin in the WM1158 cells, which also 
express MCAM and β3 integrin, does not lead to a decrease in migration or invasion. In these 
cells, however, the other two adhesion molecules may fully compensate for the loss of N-
cadherin function. On the other hand, it is possible that inhibiting N-cadherin in a cell line that 
does not also express MCAM and β3 integrin may lead to inhibition of cell migration and/or 
invasion. It would therefore be useful, if feasible, to identify a melanoma cell line that expresses 
N-cadherin, but not MCAM or β3 integrin, and determine whether migration and invasion are 
impaired when N-cadherin expression is inhibited in the absence of these adhesion molecules 
with redundant functions.  
Furthermore, although the MGP melanoma cell lines utilized in our experiments co-
express N-cadherin, MCAM, and β3 integrin, the TMA data clearly demonstrate that only about 
50% of metastatic melanoma patients express all three. Thus, in the clinic, the efficacy of 
individual or combined targeting of adhesion molecules may differ based on whether an 
individual patient’s melanoma expresses only one or two adhesion molecules versus all three. 
Therefore, before initiating a therapeutic regimen, it would be important to evaluate which cell 
adhesion molecules a particular melanoma expresses, to help determine which patients are most 
likely to respond to a given treatment.  
Taken as a whole, our results support the hypothesis that therapeutic strategies that target 
a combination of adhesion molecules may induce a more pronounced impairment of melanoma 
cell migration and invasion compared with targeting only a single molecule.  
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7.0  INHIBITION OF N-CADHERIN, MCAM, OR BETA 3 INTEGRIN IN VIVO 
7.1 INTRODUCTION 
In addition to the in vitro studies described above, a second aim of this dissertation was to 
determine the impact of inhibiting the expression of N-cadherin, MCAM, and/or β3 integrin in 
melanoma xenografts, by examining the potential for tumor regression and/or decreased 
metastasis formation. These in vivo studies have the potential to provide additional preliminary 
evidence regarding whether inhibition of cell adhesion molecules represents a viable therapeutic 
approach for melanoma. We used two approaches to investigate this question: analysis of the 
growth patterns of the N-cadherin, MCAM, or β3 integrin stable antisense-transfected cells in 
vivo, and direct intratumoral injection of antisense plasmids targeting individual adhesion 
molecules in established melanoma xenografts. In previous studies, our lab demonstrated 
successful inhibition of bFGF/FGFR-1 expression in xenografts via intratumoral injection of 
antisense plasmid (Li et al., 1996; Wang and Becker, 1997; Valesky et al., 2002). This chapter 
will discuss the approaches and challenges associated with our goal, as well as alternative 
methods that may be used in future investigations.  
 68 
7.2 RESULTS 
7.2.1 Tumor-forming ability of N-cadherin, MCAM, and β3 integrin antisense 
transfectants  
In the previous chapters, I described the generation of MGP melanoma cells transfected with 
antisense-oriented N-cadherin, MCAM, or β3 integrin plasmid. Our next objective was to 
determine whether the antisense transfectants would form tumors in nude mice, and if so, 
whether the tumors would grow at a reduced rate compared to control cells. In order to assess the 
growth and tumor-forming ability of these antisense-transfected cells in an in vivo setting, we 
subcutaneously injected 5x106 non-transfected, vector only-transfected, or antisense-transfected 
cells into each nude mouse. Two mice were injected per cell line. Tumor size was measured until 
the tumors reached a maximum of 2 cm in perpendicular diameter. Tumor volume for each 
experimental group is illustrated in Figure 27. The growth of N-cadherin, MCAM, or β3 integrin 
antisense-transfected cells was substantially reduced (between 2 to 8 fold) compared with non-
transfected control cells, beginning as early as day 21 following injection. However, the growth 
of two vector-transfected cell lines was equally impaired. This experiment was repeated twice, 
with the same result. Therefore, conclusive results regarding the in vivo growth potential of the 
antisense-transfected cells could not be obtained.  
One possible explanation for the technical difficulties encountered with this approach is 
the impact of growing the cell lines in the selective antibiotic hygromycin prior to injection. It is 
possible that cells grown in hygromycin have impaired ability to establish as a tumor in vivo. We 
do not believe that the nonspecific inhibition of in vivo growth is a direct consequence of the 
pcDNA vector itself, because we determined that melanoma cells transfected with a different 
vector control (pREP7-RSV, Invitrogen, for episomal expression) also exhibited impaired 
growth in vivo (data not shown).  
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Figure 27: Growth of antisense-transfected cells in nude mice  
N-cadherin, MCAM, or β3 integrin antisense-transfected WM98B melanoma cells, pcDNA vector only-
transfected cells, or non-transfected cells were injected subcutaneously into nude mice (5x106 cells per 
mouse). Tumor size was measured three times per week, and tumor volume was calculated using the 
formula: [(Length x Width2)/2].   
7.2.2 Direct intratumoral targeting of N-cadherin, MCAM, or β3 integrin in established 
human melanoma xenografts  
While in the previous section we asked whether melanoma cells transfected with antisense-
oriented N-cadherin, MCAM, or β3 integrin would exhibit reduced tumor formation and/or tumor 
growth, our next goal was to determine whether we could inhibit expression of the three 
adhesion molecules in established melanoma xenografts. The latter method is therapeutically 
more relevant compared with the in vivo analysis of the antisense transfectants. As mentioned 
above, our lab previously demonstrated successful inhibition of bFGF/FGFR-1 expression in 
xenografts, through intratumoral injection of antisense plasmid, using DcChol liposomes as the 
delivery reagent (Li et al., 1996). However, prepared DcChol liposomes are no longer available. 
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Therefore, it was necessary to identify a new source of lipid particles for intratumoral delivery of 
the plasmid constructs.  
We utilized several approaches to develop an experimental protocol whereby antisense 
plasmids could be efficiently expressed in vivo and yield subsequent downregulation of 
expression of the targeted molecule in a melanoma xenograft. First, pREP7-TYR vectors (driven 
by the tyrosinase promoter, which is expressed in cells of melanocytic origin), containing sense 
or antisense-oriented β3 integrin cDNA, were injected intratumorally into melanoma xenografts, 
using Lipofectamine 2000 as the delivery reagent. However, we did not observe significant 
differences in the growth of xenografts injected with antisense or sense β3 integrin plasmid, 
compared with controls, which included no injection, Lipofectamine 2000 only, or empty 
pREP7-TYR vector (Figure 28).  
 
Figure 28: Melanoma xenografts injected intratumorally with sense or antisense-oriented β3 
integrin pREP7-TYR plasmid do not display altered growth 
Three mice per vector construct were injected intratumorally with Lipofectamine 2000, pREP7-TYR 
vector, sense-oriented β3 integrin pREP7-TYR vector, or antisense-oriented β3 integrin pREP7-TYR 
vector. Two mice received no injection. 100 µg of plasmid DNA was used for the first injection, with 50 
µg for each injection thereafter. 3 µg of Lipofectamine 2000 was complexed with the plasmid DNA for 
each injection. The arrow indicates the first day of plasmid intratumoral injections.  
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Next, to determine the expression of β3 integrin following injection of sense or antisense-
oriented β3 integrin plasmid, we probed the tumors for β3 integrin through standard 
immunohistochemistry. Selected tumors are shown in Figure 29. Overall, β3 integrin levels are 
unchanged in sense or antisense-injected tumors, compared with controls. However, β3 integrin 
expression is slightly decreased in a small part of the antisense-injected tumor (lower left-hand 
corner of image).  
 
Figure 29: Expression of β3 integrin is not significantly altered in tumors injected with sense or 
antisense-oriented β3 integrin pREP7-TYR plasmids 
Snap-frozen tumors were embedded in O.C.T., sectioned, and stained by standard immunohistochemistry 
for expression of β3 integrin protein.  
 
Given our finding that β3 integrin expression was not significantly decreased in the 
tumors injected with antisense β3 integrin plasmid vector, we extracted DNA from the tumors 
and performed PCR to determine the presence or absence of each plasmid. The sense-oriented β3 
integrin plasmid is present in the tumors injected with this plasmid, but as expected, is absent in 
tumors receiving either no injection, vector only, or antisense β3 integrin plasmid (Figure 30, left 
panel). Purified β3 integrin sense plasmid served as a positive control. Likewise, β3 integrin 
antisense plasmid is present only in the tumors that were injected with this plasmid. Purified β3 
integrin antisense plasmid served as a positive control (Figure 30, right panel). These results 
indicate that the plasmids were delivered to the tumor cells. However, the immunostaining data 
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suggest that the antisense transcript may not be expressed at sufficiently high levels to produce 
downregulation of the endogenous β3 integrin transcript.  
 
 
Figure 30: β3 integrin sense and antisense pREP7-TYR plasmid DNA is present in tumors injected 
intratumorally with each respective vector 
DNA was extracted from snap-frozen tumors, and PCR was performed to amplify the sense or antisense 
β3 integrin plasmid vector (1.3 kb fragment).  
 
The previous experiment was repeated, using 5 µg of Lipofectamine 2000 (rather than 3 
µg) per injection, complexed with β3 integrin sense or antisense plasmid vector. In addition, one 
mouse each was injected intratumorally with N-cadherin or MCAM antisense-oriented pREP7-
TYR plasmid. The growth of melanoma xenografts following injection of β3 integrin sense or 





Figure 31: Melanoma xenografts injected intratumorally with β3 integrin sense or antisense-
oriented pREP7-TYR plasmid do not display significant alterations in growth 
Three mice per vector construct were injected intratumorally with Lipofectamine 2000 alone, empty 
pREP7-TYR vector, sense-oriented β3 integrin pREP7-TYR vector, or antisense-oriented β3 integrin 
pREP7-TYR vector. Two mice received no injection. 100 µg of plasmid DNA was used for the first 
injection, with 50 µg for each injection thereafter. 5 µg of Lipofectamine 2000 was complexed with the 
plasmid DNA for each injection. The arrow indicates the first day of intratumoral plasmid injections.  
 
For a second time, the growth of the xenografts was not significantly altered following 
injection of β3 integrin sense or antisense plasmid. Immunoblot analysis illustrates that in tumors 
injected with β3 integrin antisense plasmid, levels of β3 integrin protein were only slightly 
decreased compared with controls. In the mice injected with N-cadherin or MCAM antisense 
plasmid, levels of each respective protein were unchanged (Figure 32).  
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Figure 32: N-cadherin, MCAM, and β3 integrin protein levels are not significantly decreased in 
tumors following intratumoral injection with antisense pREP7-TYR plasmids targeting each 
adhesion molecule  
Protein was isolated from snap-frozen tumors and analyzed by immunoblotting for expression of N-
cadherin, MCAM, or β3 integrin.  
 
The PCR data indicated that the plasmids were delivered to the cells; yet, effective 
downregulation of expression of the targeted molecules was not achieved. We hypothesized that 
the tissue-specific tyrosinase promoter may not generate high enough copy numbers of the 
antisense transcript to mediate downregulation of the targeted proteins in vivo. In order to 
address our hypothesis, we generated new N-cadherin, MCAM, and β3 integrin antisense vectors 
using the pREP7-RSV plasmid, as well as the pcDNA3.1-CMV plasmid, for expression in all 
cell types. Tumors were injected intratumorally with N-cadherin, MCAM, or β3 integrin 
antisense-oriented pREP7-RSV or pcDNA-CMV plasmid. It is important to note that only one 
tumor per plasmid was injected for this preliminary experiment, and as such, the growth results 
are likely not significant. However, the tumors injected with antisense-oriented N-cadherin, 
MCAM, or β3 integrin pREP7-RSV plasmid grew slightly slower than the control tumor, 
receiving Lipofectamine 2000 alone (Figure 33). The tumors injected with antisense-oriented N-
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cadherin or β3 integrin pcDNA-CMV plasmids great at approximately the same rate as control 
tumors (Figure 34). Although the single tumor injected with antisense-oriented MCAM pcDNA-
CMV plasmid grew slowly compared with controls, it is important to note that this tumor was 
smaller from the beginning of the experiment (Figure 34).  
 
 
Figure 33: Tumor volume of melanoma xenografts following intratumoral injection of N-cadherin, 
MCAM, or β3 integrin antisense-oriented pREP7-RSV plasmids  
One tumor per vector construct was injected with plasmid DNA complexed with 5 µg of Lipofectamine 
2000. 100 µg of plasmid DNA was used for the first injection, with 50 µg for each injection thereafter. 
The arrow indicates the first day of intratumoral injections.  
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Figure 34: Tumor volume of melanoma xenografts following intratumoral injection of N-cadherin, 
MCAM, or β3 integrin antisense-oriented pcDNA-CMV plasmids 
One tumor per vector construct was injected with plasmid DNA complexed with 5 µg of Lipofectamine 
2000. 100 µg of plasmid DNA was used for the first injection, with 50 µg for each injection thereafter. 
The arrow indicates the first day of intratumoral injections.  
 
PCR analysis of DNA extracted from these tumors showed that, in contrast to previous 
experiments, the injected plasmid DNA was detected in only some of the respective tumors 
(Figure 35). Of the six antisense plasmid vectors that were intratumorally injected, only antisense 
MCAM pcDNA-CMV and antisense β3 integrin pREP7-RSV were detected in the respective 
tumors. The control reactions, designed to amplify each purified plasmid, were all positive as 
expected. These results suggest that delivery of the plasmid DNA into the tumor cells was only 
achieved in a fraction of the tumors.  
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Figure 35: PCR analysis of plasmid DNA in intratumorally-injected melanoma xenografts 
DNA was isolated from the snap-frozen tumors, and PCR was performed to amplify each injected 
plasmid (antisense-oriented N-cadherin (2.0 kb), MCAM (1.1 kb), or β3 integrin (1.3 kb), in pREP7-RSV 
or pcDNA-CMV plasmid).  
 
Because delivery of the plasmid DNA into the tumor cells was not persistent and 
uniform, we obtained several additional transfection delivery reagents, including Mirus TransIT 
In Vivo delivery reagent, In vivo jetPEI, and GeneFECTOR/NovaFECTOR. A control pcDNA 
vector containing the LacZ reporter gene was complexed with each transfection reagent, and 
intratumorally injected into the melanoma xenografts. In addition, one mouse was injected with 
naked pcDNA LacZ plasmid. Each mouse received two injections of the pcDNA LacZ plasmid, 
two days apart. Two days after the second injection, the tumors were extracted, snap-frozen, and 
assayed for expression of β-galactosidase. However, we were unable to detect expression of β-
galactosidase, using any of the delivery methods, as evidenced by a lack of tumor cells stained 
blue (images not shown).  
In parallel, mice were also injected with Mirus TransIT or jetPEI reagent, complexed 
with N-cadherin, MCAM, or β3 integrin antisense pcDNA-CMV plasmid, so that the protein 
levels could be examined in these tumors. The tumor injected with antisense β3 integrin plasmid 
with MIRUS delivery reagent grew faster compared with the other tumors, which all grew at 
approximately the same rate (Figure 36). Again, it is important to note, that only one mouse was 
utilized per group for this experiment. Immunoblot analyses illustrated that in the case of N-
cadherin and MCAM, levels of the targeted protein were still unchanged. In the case of β3 
integrin, protein levels were also unchanged, although an unexplained shift in band size was 
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Figure 36: Tumor volume of melanoma xenografts intratumorally injected with antisense N-
cadherin, MCAM, or β3 integrin pcDNA-CMV plasmid, using jetPEI or MIRUS delivery reagent  
One tumor per vector construct was injected with antisense N-cadherin, MCAM, or β3 integrin pcDNA-
CMV plasmid complexed with jetPEI or MIRUS delivery reagent, as described in Section A.2.2. Control 





Figure 37: Expression of N-cadherin, MCAM, and β3 integrin protein is unchanged in tumors 
injected with antisense pcDNA-CMV constructs, using jetPEI or MIRUS delivery reagent 
Protein was isolated from the snap-frozen tumors and analyzed by immunoblot analysis, for expression of 
N-cadherin, MCAM, or β3 integrin. Control tumors were injected with pcDNA LacZ plasmid.  
7.3 DISCUSSION 
In the context of the in vivo studies, we encountered a variety of challenges. Conclusive 
differences between the growth of control versus antisense-transfected cells in nude mice could 
not be observed. This result may have been due to the fact that prior to injection, the cells were 
cultured in the antibiotic hygromycin, which may have impaired the ability of the cells to 
establish tumors in vivo. In addition, none of the intratumoral plasmid delivery techniques 
produced a significant downregulation of expression of the targeted molecules. Based on the 
PCR results, we found that delivery of the plasmid DNA into the tumor cells was inconsistent 
from experiment-to-experiment, although it was achieved in some cases. We were unable to 
detect a significant decrease in expression of N-cadherin, MCAM, or β3 integrin protein 
following intratumoral injection of any of the antisense plasmids. β-galactosidase expression was 
not detected following intratumoral injection of pcDNA-CMV plasmid containing the LacZ 
gene, using various delivery reagents. This suggests that the antisense transcripts, at least in the 
case of pcDNA-CMV, are not efficiently expressed within the tumor cells. Overall, it is likely 
that a combination of poor delivery of the plasmid into the tumors cells and insufficient 
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expression/copy number of the antisense transcripts contributed to our lack of success at 
inhibiting N-cadherin, MCAM, or β3 integrin in MGP melanoma xenografts.  
There are several alternative approaches that have been described in the literature and 
might be used in future experiments. Several groups have recently demonstrated that 
intratumoral injection of siRNA can effectively downregulate expression of specific genes (Leng 
and Mixson, 2005; Ogushi et al., 2005). Intratumoral injection of siRNAs has the advantage of 
directly paralleling the in vitro siRNA methods utilized to inhibit N-cadherin, MCAM, and β3 
integrin in this dissertation. If effective, one might also readily achieve simultaneous inhibition 
of N-cadherin, MCAM, and β3 integrin expression in vivo. In fact, simultaneous inhibition of two 
genes through intratumoral injection of siRNA has been recently reported (Ducker et al., 2005). 
Similarly, one might utilize antisense oligonucleotides to inhibit expression of the adhesion 
molecules in vivo, which would present many of the same benefits described for siRNAs.  
In the future, it will be important to examine the individual and simultaneous inhibition 
of N-cadherin, MCAM, and β3 integrin in an in vivo setting, where the tumor microenvironment 
may play a substantial role in tumor growth and metastasis. Once an effective method is 
achieved for inhibition of N-cadherin, MCAM, and/or β3 integrin in an in vivo setting, these 
additional questions can be addressed.  
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8.0  A FUNCTION-BLOCKING ANTIBODY TARGETING ALPHA V BETA 3 
INTEGRIN DOES NOT IMPAIR THE PROLIFERATION OF HUMAN MGP 
MELANOMA CELLS OR THE GROWTH OF MELANOMA XENOGRAFTS 
Over the last decade, blocking the function of specific molecules by way of antibodies has 
become one of several promising approaches for cancer therapeutics. The monoclonal antibody, 
Herceptin, which blocks HER2 protein, is an example of a targeted therapy for HER2-positive 
breast cancers (as reviewed by Yeon and Pegram, 2005). Similarly, in the case of integrins, 
several antibodies that target specific integrin α or β subunits, or αβ complexes, are being 
investigated for their therapeutic efficacy.  
The first antibody targeting the αvβ3 integrin complex was developed about a decade ago. 
This function-blocking mouse monoclonal antibody, called LM609, has specificity for human 
αvβ3 integrin (Cheresh and Spiro, 1987). Studies showed that when human tumor fragments were 
implanted onto the chicken chorioallantoic membrane (CAM), LM609 impaired angiogenesis 
and resulted in tumor regression (Brooks et al., 1994). The M21-L human melanoma cells used 
in this study did not express αvβ3 integrin, which indicated that the tumor regression was due to 
inhibition of angiogenesis of the tumor neovasculature, and not an inhibition of αvβ3 integrin on 
the melanoma cells. In subsequent experiments, LM609 was also shown to decrease the 
transendothelial migration of melanoma cells in culture (Voura et al., 2001). Studies were then 
expanded to an in vivo setting, whereby it was shown that LM609 treatment decreased the 
formation of metastases of human M21 melanoma cells, and increased animal survival (Felding-
Habermann et al., 2002).  
Based on these promising data, a humanized LM609 antibody, Abegrin® (Vitaxin, 
MEDI-522), was generated and tested in clinical trials (Wu et al., 1998). A Phase I trial, 
comprised of patients with various types of late stage cancer, demonstrated that Abegrin was 
well-tolerated. In addition, one patient had a partial response, and seven patients showed stable 
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disease (Gutheil et al., 2000). However, not all of the results were as promising. In another Phase 
I trial of metastatic melanoma patients, Abegrin caused little toxicity, but no anti-tumor 
responses were reported (Posey et al., 2001), while in a Phase I trial comprised of patients with 
advanced leiomyosarcoma, Abegrin was well-tolerated, but, again, no tumor response was 
observed (Shreyaskumar et al., 2001). On the other hand, preliminary results from an ongoing 
Phase II trial designed to test the efficacy of the Abegrin antibody in stage IV melanoma patients 
demonstrated that although patients treated with Abegrin had no objective tumor response, they 
lived longer compared to historic controls (Hersey et al., 2005).  
In light of these ongoing trials, we examined the proliferation of MGP melanoma cells 
treated with Abegrin, both in vitro and in vivo, with the goal of addressing the hypothesis that 
Abegrin may impair melanoma cell proliferation. This set of experimental assays enabled us to 
make a preliminary assessment of the consequence of inhibiting αvβ3 integrin in melanoma cells 
in vivo, as well as to compare the results of the siRNA/antisense-mediated inhibition of β3 
integrin in vitro to an antibody-mediated approach.  
8.1 RESULTS 
8.1.1 Proliferation of human MGP melanoma cells is not impaired by a function-blocking 
αvβ3 integrin antibody, Abegrin  
We first examined the effect of the αvβ3 integrin function-blocking antibody, Abegrin, on the 
proliferation of the MGP melanoma cell lines WM1158 and WM983B. Cells were counted at 24, 
48, and 72 hours following addition of Abegrin antibody to the cell cultures. Proliferation of both 
MGP melanoma cell lines is unchanged following treatment with the antibody (Figure 38 and 
39). This is in contrast to the effect following inhibition of β3 integrin through siRNA or 
antisense targeting in the same melanoma cell lines, whereby proliferation was decreased by 
between 30 and 50%.  
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Figure 38: Abegrin does not decrease the proliferation of WM1158 cells 
WM1158 cells were seeded into 24-well plates, and 24 hours later, 50 µg/mL of Abegrin antibody diluted 
in PBS was added to the culture medium. At the indicated times following Abegrin treatment, the cells 
were detached with trypsin and counted. The data are expressed as the average of triplicate counts.  
 
 
Figure 39: Abegrin does not decrease the proliferation of WM983B cells 
WM983B cells were seeded into 24-well plates, and 24 hours later, 75 µg/mL of Abegrin antibody diluted 
in PBS was added to the culture medium. At the indicated times following Abegrin treatment, the cells 
were detached with trypsin and counted. The data are expressed as the average of triplicate counts.  
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8.1.2 Growth of established human melanoma xenografts is not impaired by intratumoral 
injection of Abegrin 
Following the in vitro proliferation analysis, our second goal was to examine the impact of 
blocking αvβ3 integrin function in vivo. WM983B MGP melanoma xenografts were generated, 
and when the tumors reached approximately 5x5 mm, Abegrin was injected intratumorally, three 
times weekly, for the duration of the experiment. Similar to the in vitro analyses, the Abegrin 
antibody does not significantly alter the growth of melanoma xenografts (Figure 40).  
 
Figure 40: Abegrin does not slow the growth of established human melanoma xenografts 
Melanoma xenografts were generated via subcutaneous injection of WM983B cells. When the tumors 
reached approximately 5x5 mm, 100 µg of Abegrin antibody, diluted in PBS, was injected intratumorally 
three times per week, until the tumors reached the maximum permissible size at day 38. Control mice 
were injected with PBS alone. Three mice were included per group.  
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8.1.3 Expression of β3 integrin and osteopontin in human melanoma xenografts injected 
with Abegrin 
In order to assess whether Abegrin had an impact on the expression of β3 integrin, the tumors 
were extracted, snap-frozen, and sectioned for standard immunohistochemistry. β3 integrin 
expression is unchanged following Abegrin injection, except for a slight decrease in Tumor 2 
(selected tumor sections are shown in Figure 41). Immunoblot analysis also showed that levels of 
β3 integrin protein are unchanged an Abegrin-treated tumor (data not shown).  
 
Figure 41: β3 integrin expression is unchanged in tumors injected with Abegrin.  
Tumors were snap-frozen, sectioned, and probed with β3 integrin antibody, through standard 
immunohistochemistry. Selected images of tumor sections are shown.  
 
As part of the whole-genome microarray analysis, we recently identified osteopontin 
(OPN, SPP1) as the gene exhibiting the most profound change in expression correlating with the 
transition from melanoma in situ to VGP melanoma (Smith et al., 2005). OPN serves as an 
extracellular matrix ligand to αvβ3 integrin, and has been associated with melanoma progression, 
proliferation, and invasion (Philip et al., 2001; Zhou et al., 2005). We hypothesized that 
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expression of OPN may be altered following the inhibition of αvβ3 integrin signaling. We 
examined the expression of OPN in the xenografts injected with Abegrin, or with PBS alone. 
However, we did not observe major differences in the expression of OPN in three tumors 
injected with Abegrin (Figure 42).  
 
 
Figure 42: OPN expression in tumors injected with Abegrin   
Tumors were snap-frozen, sectioned, and probed with OPN antibody. Selected images of tumor sections 
are shown.  
8.2 DISCUSSION 
Targeting αvβ3 integrin via a function-blocking antibody does not decrease the proliferation of 
MGP melanoma cells, in vitro or in vivo. In contrast, siRNA or antisense-mediated inhibition of 
β3 integrin expression reduces the proliferation of the MGP melanoma cells by 30-50% as 
determined in vitro. There are several possible explanations for this discrepancy. First, Abegrin 
targets and binds to the αvβ3 integrin complex, whereas siRNA or antisense-mediated inhibition 
of β3 integrin expression impacts all integrin complexes that contain β3 integrins. This may have 
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the subsequent effect of leaving the αv subunit available to interact with other β subunits. As 
such, the biological consequences of these two different targeting approaches, though similar in 
concept, may differ with respect to their impact on the melanoma cells. Second, downregulation 
of an adhesion molecule at the level of mRNA/protein expression may elicit a more potent effect 
compared to a function-blocking antibody approach, wherein the expression of the targeted 
protein could remain unchanged.  
It is worthwhile to consider our findings when examining the results of ongoing clinical 
trials of Abegrin in advanced-stage melanoma patients. Results from a Phase II clinical trial 
suggest that patients receiving Abegrin have improved survival compared with historic controls, 
but no objective tumor response (Hersey et al., 2005). In a previous study, the non-humanized 
antibody, LM609, impaired the growth of αvβ3-negative melanoma fragments implanted on the 
chicken CAM (Brooks et al., 1994) – indicating that the observed tumor regression was due to 
the anti-angiogenic effect of LM609 on the blood vessels, rather than the direct binding of the 
antibody to the melanoma cells. In light of these results, one hypothesis is that inhibition of αvβ3 
integrin in advanced-stage melanoma patients blocks angiogenesis, primarily by targeting αvβ3 
integrin on the tumor-interspersing blood vessels, rather than on the melanoma cells themselves. 
In our in vivo study, the humanized Abegrin antibody should not be expected to block αvβ3 
integrin on the mouse blood vessels – therefore, our approach examined the impact of targeting 
αvβ3 integrin on the melanoma cells only. As we observed, Abegrin does not substantially impact 
the growth of the human melanoma xenografts, perhaps due to the fact that mouse blood vessel 
growth/angiogenesis is not impaired in this setting. Taken together, our results are in agreement 
with the proposed hypothesis that Abegrin’s primary mechanism might be the inhibition of 
angiogenesis, rather than a direct impact of the antibody on the αvβ3 integrin expressed by the 
melanoma cells.  
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9.0  DISCUSSION 
9.1 SUMMARY 
The focus of this dissertation was to elucidate the role of the cell adhesion molecules N-cadherin, 
MCAM, and β3 integrin in melanoma progression, proliferation, migration, and invasion, with 
the ultimate goal of determining whether any of these genes may serve as valid and effective 
therapeutic targets for the disease. This study represents the first time that all three adhesion 
molecules have been studied in concert. We addressed the hypothesis that combined targeting of 
all three adhesion molecules might generate a more robust anti-tumor response compared with 
inhibition of each individual gene.  
Previous reports in the literature documented that N-cadherin, MCAM, and β3 integrin 
are expressed at high levels in a significant number of human metastatic melanoma cell lines and 
tissues. However, knowledge regarding the expression level of each molecule during the 
individual stages of melanoma progression was incomplete. To help fill this gap, we used whole-
genome and TMA analyses to generate a comprehensive picture of N-cadherin, MCAM, and β3 
integrin mRNA and protein expression, throughout the distinct stages of melanoma progression. 
We also documented, for the first time, the co-expression of one, two, or all three adhesion 
molecules in subcutaneous and visceral melanoma metastases. We demonstrate that although N-
cadherin and β3 integrin are melanoma progression markers, whereby expression increases from 
early to late stages of the disease, MCAM is not. MCAM is expressed in many benign and 
atypical nevi, and is also expressed at high-levels in metastatic melanomas. This suggests that 
MCAM may also function in the early stages of melanoma development.  
In addition, the TMA analysis revealed that only about 50% of the subcutaneous and 
visceral MGP melanoma tissues examined co-expressed N-cadherin, MCAM, and β3 integrin, 
but 97% expressed at least one of the three. This indicates that all three adhesion molecules need 
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not be expressed in the same melanoma for metastasis formation to occur. N-cadherin, MCAM, 
and β3 integrin may each be capable of mediating melanoma invasion and metastasis, and, as a 
result, inhibition of greater than one molecule may be required for substantial anti-tumor effects. 
We next investigated the consequence of inhibiting expression of N-cadherin, MCAM, or 
β3 integrin on the proliferation, migration, and invasion of MGP melanoma cells. First, by using 
the same cell lines and assays for inhibiting expression of each adhesion molecule, we were able 
to analyze the relative importance of N-cadherin, MCAM, and β3 integrin expression compared 
to one another. In contrast, previous studies of individual adhesion molecules were performed 
using a variety of different cell lines and experimental approaches, thus making direct 
comparisons challenging. Furthermore, the inhibition of endogenous gene expression more 
closely resembles a viable clinical therapy, compared with previous studies that, in most cases, 
involved overexpression of the adhesion molecules. Second, we demonstrate, for the first time, 
the result of simultaneously inhibiting expression of N-cadherin, MCAM, and β3 integrin in 
MGP melanoma cells.  
We show that blocking expression of N-cadherin, MCAM, or β3 integrin leads to 
decreased melanoma cell proliferation, but that simultaneous targeting of all three adhesion 
molecules does not indicate synergistic effects. Proliferation is decreased by about 50%, but is 
not completely blocked, suggesting that proliferation is maintained in the melanoma cells via a 
different signaling pathway(s). On the other hand, simultaneous inhibition of N-cadherin, 
MCAM, and β3 integrin results in a decrease in migration and invasion that is more substantial 
than that following individual inhibition of the three adhesion molecules. Therefore, the 
migration/invasion data support the hypothesis that simultaneous inhibition of multiple cell 
adhesion molecules generates a more robust anti-tumorigenic effect on the melanoma cells.  
As a final point, we show that a fully humanized αvβ3 integrin antibody, currently 
assessed in clinical trials, does not impair melanoma cell proliferation - neither in vitro nor in 
vivo. This result is in contrast to the inhibition of β3 integrin subunit expression via siRNA or 
antisense plasmids in the same melanoma cell lines, whereby proliferation was decreased. This 
finding suggests that an antisense or siRNA targeting approach, whereby the mRNA/protein is 
downregulated, may elicit a different biological response compared with a function-blocking 
antibody approach, where the antibody binds directly to the integrin target. Moreover, it is likely 
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that targeting an individual integrin subunit can generate a different cellular response than 
targeting a specific integrin alpha-beta complex.  
9.2 FUTURE DIRECTIONS 
Several avenues for future investigation can be based on the results presented in this dissertation. 
First, it will be essential to extend the work to determine the impact of inhibiting expression of 
N-cadherin, MCAM, and/or β3 integrin in mouse models. This is crucial, because in vitro 
experiments do not address the interaction of tumors cells with the tumor microenvironment - an 
event that is likely impacted by the cell-cell and cell-matrix adhesion molecules expressed both 
by tumor cells and by cells in the surrounding tumor microenvironment. In Chapter 7, I 
described our attempts to accomplish this goal; however, to date, we have been unable to achieve 
measurable downregulation of the adhesion molecules in melanoma xenografts. In the future, 
alternative approaches should be explored. Possible strategies include the use of siRNAs, shRNA 
vectors, or antisense oligonucleotides. These pre-clinical animal studies will help further 
illuminate whether targeting a combination of cell adhesion molecules is likely to represent a 
useful and effective therapeutic strategy.  
Future studies should also further investigate the signaling mechanisms of N-cadherin, 
MCAM, and β3 integrin in metastatic melanoma cells. For example, it would be valuable to 
examine the expression of additional integrin subunits, such as β1 and β5, which can also 
associate with αv integrin, following the inhibition of β3 integrin. This would help to determine 
with which β subunit αv integrin associates following the downregulation of β3 integrin, and to 
investigate whether this alternative integrin complex has the ability to mediate cell proliferation, 
migration, and/or invasion.  
In addition, a physical association between FGFR-1 and N-cadherin has been 
demonstrated in breast cancer cells (Suyama et al., 2002), which results in persistent activation 
of MAPK/ERK and enhanced cell invasion. However, this phenomenon has not been 
investigated in melanoma cells to date. Given that bFGF/FGFR-1 are known to play a key role in 
melanoma proliferation (Becker et al., 1992; Wang and Becker, 1997; Valesky et al., 2002), it 
would be worthwhile to investigate whether a direct association between N-cadherin and FGFR-
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1 occurs in melanoma cells, and whether a loss of such association may be linked to the 
impairment of melanoma cell proliferation following inhibition of N-cadherin expression.  
Finally, we showed that inhibition of MCAM or β3 integrin had a more pronounced effect 
upon melanoma cell migration and invasion compared with inhibition of N-cadherin alone. For 
this reason, inhibition of the specific combination of MCAM and β3 integrin should be explored, 
to determine whether this combination is equally effective compared with inhibition of all three 
adhesion molecules.  
9.2.1 Clinical Applications  
The data from this dissertation also point to avenues for future investigation in a clinical setting. 
First, it would be worthwhile to explore whether there is a correlation between co-expression of 
N-cadherin, MCAM, and/or β3 integrin and survival of patients with metastatic melanoma. We 
show that approximately 50% of MGP melanomas express all three adhesion molecules, and that 
the three adhesion molecules play a role in proliferation, migration, and invasion in vitro. This 
leads to the hypothesis that patients whose melanomas co-express all three molecules may have 
poorer prognosis/survival compared with patients whose melanomas express only one or two of 
the three adhesion molecules. The TMA technique could be used to address this question in a 
large number of patients, in the context of a retrospective clinical trial of patients whose 
progression-free and overall survival were documented.  
Translating our findings into the clinical setting has additional implications. First, 
treatment of patients with advanced-stage melanoma with, for example, an antibody or peptide 
that blocks only one of these molecules may not be as efficacious as blocking a combination of 
adhesion molecules, such as MCAM and β3 integrin. This may be of particular importance in the 
subset of patients whose melanomas express all three adhesion molecules. Therefore, sequential 
or simultaneous treatment with antagonists to multiple adhesion molecules may yield a 
noticeably greater benefit regarding progression-free and overall survival than targeting a single 
one of these adhesion molecules. Second, if indeed in the clinical setting it turns out that 
targeting cell adhesion molecules impairs the formation of additional metastases and/or causes 
tumor regression, it may be desirable to establish their most effective combination, as N-
cadherin, MCAM, and β3 integrin likely do not represent the only therapeutic targets.  
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In recent years, combined treatment modalities have generated significant attention in 
clinical trials. In this dissertation, I suggest that inhibiting a combination of cell adhesion 
molecules may generate a more robust therapeutic response compared with targeting a single one 
of them. To take this approach even further, one might also combine inhibitors of cell adhesion 
molecules with cytotoxic agents, such as dacarbazine and cisplatin, which interfere with DNA 
replication and cause cell death. It is likely that in the case of melanoma, it may be necessary to 
combine an inhibitor of a cell adhesion molecule(s) with a cytotoxic drug, to elicit the most 
effective tumor response. To make a preliminary assessment of this hypothesis, siRNA or 
antisense-transfected melanoma cells could be treated with various chemotherapeutic reagents, 
such as such as dacarbazine, cisplatin, or paclitaxel, and the relative effect upon proliferation, 
migration, and/or invasion examined. If promising, this approach could be extended to in vivo 
models.  
In summary, the proposed experiments will further our understanding of the biological 
function(s) of N-cadherin, MCAM, and β3 integrin in metastatic melanoma, and help determine 
whether simultaneous targeting of multiple adhesion molecules is an approach that should be 
taken to the clinic.  
9.3 CONCLUDING REMARKS 
The development of novel therapies for treatment of advanced-stage melanoma is essential, and 
the identification of genes that may serve as viable targets will facilitate this goal. We have 
characterized the expression of N-cadherin, MCAM, and β3 integrin throughout the stages of 
melanoma progression, and shown that simultaneous downregulation of the expression of all 
three adhesion molecules represents a valuable approach for inhibition of melanoma cell 
proliferation, migration, and invasion. Our findings contribute to a better understanding of the 
function of N-cadherin, MCAM, and β3 integrin in metastatic melanoma, and provide the 
foundation for future work targeting the cell adhesion molecules N-cadherin, MCAM, and β3 
integrin in a clinical setting.  
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